



US 20140248685A1

(19) **United States**(12) **Patent Application Publication**
Borchert et al.(10) **Pub. No.: US 2014/0248685 A1**(43) **Pub. Date: Sep. 4, 2014**(54) **ALPHA-AMYLASE MUTANTS**(71) Applicant: **NOVOZYMES A/S**, Bagsvaerd (DK)(72) Inventors: **Torben Vedel Borchert**, Copenhagen O (DK); **Allan Svendsen**, Birkerød (DK); **Carsten Andersen**, Værløse (DK); **Bjarne Nielsen**, Virum (DK); **Torben Laugesgaard Nissen**, Frederiksberg (DK); **Søren Kjaerulff**, Værløse (DK)(73) Assignee: **NOVOZYMES A/S**, Bagsvaerd (DK)(21) Appl. No.: **14/163,585**(22) Filed: **Jan. 24, 2014****Related U.S. Application Data**

(60) Continuation of application No. 11/953,532, filed on Dec. 10, 2007, now abandoned, which is a division of application No. 10/980,923, filed on Nov. 4, 2004, now abandoned, which is a continuation of application No. 10/665,667, filed on Sep. 19, 2003, now abandoned, which is a division of application No. 09/769,864, filed on Jan. 25, 2001, now Pat. No. 6,673,589, which is a

division of application No. 09/183,412, filed on Oct. 30, 1998, now Pat. No. 6,204,232.

(60) Provisional application No. 60/093,234, filed on Jul. 17, 1998, provisional application No. 60/064,662, filed on Nov. 6, 1997.

(30) **Foreign Application Priority Data**Oct. 30, 1997 (DK) PA 1240/97
Jul. 14, 1998 (DK) PA 1998 00936**Publication Classification**(51) **Int. Cl.**
C12N 9/28 (2006.01)(52) **U.S. Cl.**
CPC **C12N 9/2417** (2013.01)
USPC **435/202**(57) **ABSTRACT**

The invention relates to a variant of a parent Termamyl-like α -amylase, which exhibits an alteration in at least one of the following properties relative to said parent α -amylase: i) improved pH stability at a pH from 8 to 10.5; and/or ii) improved Ca^{2+} stability at pH 8 to 10.5, and/or iii) increased specific activity at temperatures from 10 to 60° C.

	1				50
1	HHNGTNGTMM	QYFEWHLPND	GNHWNRLRDD	ASNLRNRGIT	AIWIPPAWKG
2	..NGTNGTMM	QYFEWYLPND	GNHWNRLRSD	ASNLKDKGIS	AVWIPPAWKG
3	HHNGTNGTMM	QYFEWYLPND	GNHWNRLRDD	AANLKSKGIT	AVWIPPAWKG
4	VNGTLM	QYFEWYTPND	GQHWKRLQND	AEHLSDIGIT	AVWIPPAYKG
5	..ANLNGTLM	QYFEWYMPND	GQHWRRRLQND	SAYLAEHGIT	AVWIPPAYKG
6	.AAPFNGTMM	QYFEWYLPDD	GTLWTKVANE	ANNLSSLGIT	ALWLPPAYKG
	51				100
1	TSQNDVGYGA	YDLYDLGEFN	QKGTVRTKYG	TRSQLESIAH	ALKNNGVQVY
2	ASQNDVGYGA	YDLYDLGEFN	QKGTIRTKYG	TRNQLQAAVN	ALKSNGIQVY
3	TSQNDVGYGA	YDLYDLGEFN	QKGTVRTKYG	TRNQLQAAVT	SLKNNGIQVY
4	LSQSDNGYGP	YDLYDLGEFQ	QKGTVRTKYG	TKSELQDAIG	SLHSRNVQVY
5	TSQADVGYGA	YDLYDLGEFH	QKGTVRTKYG	TKGELQSAIK	SLHSRDINVY
6	TSRSDVGYGV	YDLYDLGEFN	QKGTVRTKYG	TKAQYLQAIQ	AAHAAGMQVY
	101				150
1	GDVVMNHKGG	ADATENVLAV	EVNPNNRNQE	ISGDYTIEAW	TKFDFPGRGN
2	GDVVMNHKGG	ADATEMVRVAV	EVNPNNRNQE	VSGEYTIEAW	TKFDFPGRGN
3	GDVVMNHKGG	ADGTEIVNAV	EVNRSNRNQE	TSGEYAIEAW	TKFDFPGRGN
4	GDVVLNHKAG	ADATEDVTAV	EVNPNARNQE	TSEEQIKAW	TDFRFPGRGN
5	GDVVINHKGG	ADATEDVTAV	EVDPADNRNV	ISGEHLIKAW	THFHFPGRGS
6	ADVVFDPKGG	ADGTEWVDAV	EVNPSDRNQE	ISGTYQIQAW	TKFDFPGRGN
	151				200
1	TYSDFKWRWY	HFDGVDWDQS	RQFQNRIYKF	RGDGKAWDWE	VDSENGNYDY
2	THSNFKWRWY	HFDGVDWDQS	RKLNNRIYKF	RGDGKGWDWE	VDTENGNYDY
3	NHSSFKWRWY	HFDGTDWDQS	RQLQNKIYKF	RGTGKAWDWE	VDTENGNYDY
4	TYSDFKWHWY	HFDGADWDES	RKL.SRIFKF	RGEGKAWDWE	VSENGNYDY
5	TYSDFKWHWY	HFDGTDWDES	RKL.NRIYKF	..QGKAWDWE	VSNENGNYDY
6	TYSSFKWRWY	HFDGVDWDES	RKL.SRIYKF	RGIGKAWDWE	VDTENGNYDY

Fig. 1(a)

	201				250
1	LMYADVDMDH	PEVVNELRRW	GEWYTNTLNL	DGFRIDAVKH	IKYSFTRDWL
2	LMYADIDMDH	PEVVNELRNW	GVWYTNTLGL	DGFRIDAVKH	IKYSFTRDWS
3	LMYADVDMDH	PEVIHELNRW	GVWYTNTLNL	DGFRIDAVKH	IKYSFTRDWL
4	LMYADVVDYDH	PDVVAETKKW	GIWYANELSL	DGFRIDAAKH	IKFSFLRDWV
5	LMYADIDYDH	PDVAAEIKRW	GTWYANELQL	DGFRIDAVKH	IKFSFLRDWV
6	LMYADLDMDH	PEVVTELKNW	GKWYVNTTNI	DGFRIDAVKH	IKFSFFPDWL
	251				300
1	THVRNATGKE	MFAVAEFWKN	DLGALENYLN	KTNWNHSVFD	VPLHYNLYNA
2	IHVRSATGKN	MFAVAEFWKN	DLGAIENYLN	KTNWNHSVFD	VPLHYNFYNA
3	THVRNTTGKP	MFAVAEFWKN	DLGAIENYLN	KTSWNHSAFD	VPLHYNLYNA
4	QAVRQATGKE	MFTVAEYWQN	NAGKLENYLN	KTSFNQSVFD	VPLHFNLQAA
5	NHVREKTGKE	MFTVAEYWQN	DLGALENYLN	KTNFNHSVFD	VPLHYQFHAA
6	SYVRSQTGKP	LFTVGEYWSY	DINKLHNYIT	KTDGTMSLFD	APLHNKFYTA
	301				350
1	SNSGGNYDMA	KLLNGTVVQK	HPMHAVTFVD	NHDSQPGESL	ESFVQEWFKP
2	SKSGGNYDMR	QIFNGTVVQR	HPMHAVTFVD	NHDSQPPEAL	ESFVEEWFKP
3	SNSGGYYDMR	NILNGSVVQK	HPTHAVTFVD	NHDSQPGQAL	ESFVQQWFKP
4	SSQGGGYDMR	RLLDGTVVSR	HPEKAVTFVE	NHDTQPGQSL	ESTVQTFWKP
5	STQGGGYDMR	KLLNGTVVSK	HPLKSVTFVD	NHDTQPGQSL	ESTVQTFWKP
6	SKSGGAFTMR	TLMTNTLMKD	QPTLAVTFVD	NHDTQPGQAL	QSWVDPWFKP
	351				400
1	LAYALILTRE	QGYPVVFYGD	YYGIPTHS..	.VPAMKAKID	PILEARQNFA
2	LAYALTLTRE	QGYPVVFYGD	YYGIPTHG..	.VPAMKSKID	PILEARQKYA
3	LAYALVLTRE	QGYPVVFYGD	YYGIPTHG..	.VPAMKSKID	PLLQARQTFA
4	LAYAFILTRE	SGYPQVFYGD	MYGTKGTSFK	EIPSLKDNIE	PILKARKEYA
5	LAYAFILTRE	SGYPQVFYGD	MYGTKGDSQR	EIPALKHKIE	PILKARKQYA
6	LAYAFILTRQ	EGYPCVFYGD	YYGIPQYN..	.IPSLKSKID	PLLIARRDYA
	401				450
1	YGTQHDYFDH	HNIIGWTREG	NTTHPNISGLA	TIMSDGPGGE	KWMYVGQNK
2	YGRQN.....				
3	YGTQHDYFDH	HDIIGWTREG	NSSHPNISGLA	TIMSDGPGGN	KWMYVGKNA
4	YGPQHDIYDH	PDVIGWTREG	DSSAAKISGLA	ALITDGPGGG	KRMYAGLKNA
5	YGAQHDIYDH	HDIIGWTREG	DSSVANISGLA	ALITDGPGGG	KRMYVGRQNA
6	YGTQHDYLDH	SDIIGWTREG	GTEKPGISGLA	ALITDGPGGG	KWMYVGKQHA

Fig. 1 (b)

	451					500
1	GQVWHDITGN	KPGFTVTINAD	GWANFSVNNGG	SVSIWVKR..		
2						
3	GQVWRDITGN	RTGTVTINAD	GWGNFSVNNGG	SVSVWVKQ..		
4	GETWYDITGN	RSDTVKIGSD	GWGEFHVNDG	SVSIYVQ...		
5	GETWHDITGN	RSEPVINSE	GWGEFHVNGG	SVSIYVQR..		
6	GKVFYDLTGN	RSDTVTINS	DGWGEFKNNGG	SVSVWVPRKT	TVSTIARPI	
	501		519			
1						
2						
3						
4						
5						
6	TRPWTGEFVR	WTEPRLVAW				

Fig. 1 (c)




Fig. 2




Fig. 3

1				50
1	MKFVLLLSLI	GFCWAQYDPH	TSDG.RTAIV	HLFEWRWVDI AKECERYLAP
2	LLSLI	GFCWAQYDPH	TADG.RTAIV	HLFEWRWADI AKECERYLAP
3	QYAPQ	TQSG.RTDIV	HLFEWRWVDI	ALECERYLGP
4	MKFVLLLSFTI	GFCWAQYSPN	TQQG.RTSIV	HLFEWRWVDI ALECERYLAP
5	MKLNKIITTA	GLSLGLLLPS	IATATPTTFV	HLFEWNWQDV AQECEQYLG
51				100
1	KGFGGVQVSP	PNENVVHNP	SRPWWERYQP	ISYKICTRSG NEDEFDRMVT
2	KGFGGVQVSP	PNENIIINNP	SRPWWERYQP	ISYKICSRSG NENEFKDMVT
3	KGFGGVQVSP	PNENVVVTNP	SRPWWERYQP	VSYKLCTRSG NENEFDRMVT
4	KGFGGVQVSP	PNENVAIYNP	FRPWWERYQP	VSYKLCTRSG NEDEFNRMVT
5	KGYAAVQVSP	PNEHI....T	GSQWWTRYQP	VSYELQSRGG NRAQFIDMVN
101				150
1	RCNNVGVRIY	VDAVINHMC	AGNPAGTSST	CGSYLNPNNR EFPVPYSAW
2	RCNNVGVRIY	VDAVINHMC	SGNSAGTHST	CGSYFNPNNR EFSVPYSAW
3	RCNNVGVRIY	VDAVINHMC	SGAAAGTGTT	CGSYCNPGNR EFPVPYSAW
4	RCNNVGVRIY	VDAVINHMC	NAVSAGTSST	CGSYFNPGRS DFPVPYSGW
5	RCSAAGVDIY	VDTLINHM..	.AAGSGTGTA	GNSF...GNK SFPI..YSPQ
151				200
1	DFNDNKC..	.GEIDNYNDA	YQVRNCRLTG	LLDLALEKDY VRTKVADYMN
2	YFNDNKC..	.GEINNYNDA	NQVRNCRLSG	LLDLALDKDY VRTKVADYMN
3	DFNDGKCKTA	SGGIESYNDP	YQVRDCQLVG	LLDLALEKDY VRSMIADYLN
4	DFNDGKCKTG	SGDIENYNDA	TQVRDCRLTG	LLDLALEKDY VRSKIAEYMN
5	DFHES..CTIN	NSDYG..NDR	YRVQNCCLVG	LADLDASNY VQNTIAAYIN
201				250
1	HLIDIGVAGF	RLDAAKHMWP	LDIKAVLDKL	HNLNTKWFSQ GSRPFIFQEV
2	NLIDIGVAGF	RLDAAKHMWP	LDIKAVLDKL	HNLNTKWFSQ GSRPFIFQEV
3	KLIDIGVAGF	RLDASKHMWP	LDIKAVLDKL	HNLNTNWFFPA GSRPFIFQEV
4	HLIDIGVAGF	RLDASKHMWP	LDIKAILDKL	HNLNSNWFFPA GSKPFIFQEV
5	DLQAIGVKGF	RFDASKHVAA	SDIQSLMAKV	N.....GSPVVFQEV
251				300
1	IDLGGEAIKG	SEYFGNGRVT	EFKYGAKLGT	VIRKWNGEKM SYLKNWGEW
2	IDLGGEAIKG	SEYFGNGRVT	EFKYGAKLGT	VIRKWNGEKM SYLKNWGEW
3	IDLGGEAIKS	GEYFSNGRVT	EFKYGAKLGT	VVRKWSGEKM SYLKNWGEW
4	IDLGGEPIKS	SDYFGNGRVT	EFKYGAKLGT	VIRKWNGEKM SYLKNWGEW
5	IDQGGAEVGA	SEYLSLGLVT	EFKYSTELGN	TFR...NGSL AWLSNFGGEW
301				350
1	GLVPSDRALV	FVDNHDNQRG	HGAGGSSILT	FWDARMYKMA VGFMALHPYG
2	GFVPTDRALV	FVDNHDNQRG	HGAGGASILT	FWDARMYKMA VGFMALHPYG
3	GFMPSDRALV	FVDNHDNQRG	HGAGGSSILT	FWDAYRKLVA VGFMALHPYG
4	GFVPSDRALV	FVDNHDNQRG	HGAGGASILT	FWDARLYKMA VGFMALHPYG
5	GFMPSSSAVV	FVDNHDNQRG	HGGAG.NVIT	FEDGRLYDLA NVFMALHPYG
351				400
1	FTRVMSSYRW	NRNFQNGKDQ	NDWIGPPNNN	GVTKEVTINA DTTCGNDWVC
2	FTRVMSSYRR	TRNFQNGKDV	NDWIGPPNNN	GVTKEVTINP DTTCGNDWVC
3	FTRVMSSYRW	ARNFVNGEDV	NDWIGPPNNN	GVIKEVTINA DTTCGNDWVC
4	FTRVMSSYRW	PRQFQNGNDV	NDWVGPPNNN	GVIKEVTINP DTTCGNDWVC
5	YPKVMSSY..	..DFHGDGTD	GGPNVPVHNN	GNLE.....CFASNWK

Fig. 4 (a)

```

401
1 EHRWRQIRNM VAFRNVVNGQ .PFSNWWDDN SNQVAFSRGN RGFIVENNDD
2 EHRWRQIRNM VAFRNVVNGQ .PFANWWDDNG SNQVAFSRGN RGFIVENNDD
3 EHRWREIRNM VAFRNVVDGE .PFANWWDDNG SNQVAFGRGN RGFIVENNDD
4 EHRWRQIRNM VAFRNVVDGQ .PFTNWWDDNG SNQVAFGRGN RGFIVENNDD
5 EHRWSYIAGG VAFRNVVDGQ .PFTNWWDDNG SNQVAFGRGN RGFIVENNDD

451
1 WALSATLQTG LPAGTYCDVI SGDKVDG..N CTGLRVNVGS DGKAHFSISN
2 WALSSTLQTG LPAGTYCDVI SGDKVNG..N CTGLKVVNVS DGKAHFSISN
3 WQLSSTLQTG LPAGTYCDVI SGDKVGN..S CTGIKVVVSS DGKAQFSISN
4 WSFSLTLQTG LPAGTYCDVI SGDKING..N CTGIKIYVSD DGKAHFSISN
5 STLTATVQTD MASGQYCNVL KGELSADAKS CSGEVITVNS DGTINLNIGA

501
1 SAEDPFIAIH ADSKL.....
2 SAEDPFIAIH ADSKL.....
3 SAEDPFIAIH AESKL.....
4 SAEDPFIAIH AESKL.....
5 WDA...MAIH KNAKLNTSSA S

521
```

Fig. 4 (b)

ALPHA-AMYLASE MUTANTS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. application Ser. No. 11/953,532 filed Dec. 10, 2007 (pending) which is a divisional of U.S. application Ser. No. 10/980,923, filed Nov. 4, 2004 (now abandoned), which is a continuation of U.S. application Ser. No. 10/665,667, filed Sep. 19, 2003 (now abandoned), which is a divisional of U.S. application Ser. No. 09/769,864, filed on Jan. 25, 2001 (now U.S. Pat. No. 6,673,589), which is a divisional of U.S. application Ser. No. 09/183,412, filed on Oct. 30, 1998 (now U.S. Pat. No. 6,204,232), and claims priority under 35 U.S.C. 119 of Danish application no. 1240/97, filed on Oct. 30, 1997, Danish application no. PA 1998 00936, filed on Jul. 14, 1998, U.S. provisional application No. 60/064,662, filed on Nov. 6, 1997 and U.S. provisional application No. 60/093,234, filed on Jul. 17, 1998, the contents of which are fully incorporated herein by reference.

FIELD OF THE INVENTION

[0002] The present invention relates to variants (mutants) of parent Termamyl-like α -amylases with higher activity at medium temperatures and/or high pH.

BACKGROUND OF THE INVENTION

[0003] α -Amylases (α -1,4-glucan-4-glucanohydrolases, EC 3.2.1.1) constitute a group of enzymes which catalyze hydrolysis of starch and other linear and branched 1,4-glucosidic oligo- and polysaccharides.

[0004] There is a very extensive body of patent and scientific literature relating to this industrially very important class of enzymes. A number of α -amylases such as Termamyl-like α -amylases variants are known from e.g. WO 90/11352, WO 95/10603, WO 95/26397, WO 96/23873 and WO 96/23874.

[0005] Among more recent disclosures relating to α -amylases, WO 96/23874 provides three-dimensional, X-ray crystal structural data for a Termamyl-like α -amylase which consists of the 300 N-terminal amino acid residues of the *B. amyloliquefaciens* α -amylase (BANTM) and amino acids 301-483 of the C-terminal end of the *B. licheniformis* α -amylase comprising the amino acid sequence (the latter being available commercially under the tradename TermamylTM), and which is thus closely related to the industrially important *Bacillus* α -amylases (which in the present context are embraced within the meaning of the term "Termamyl-like α -amylases", and which include, inter alia, the *B. licheniformis*, *B. amyloliquefaciens* (BANTM) and *B. stearothermophilus* (BSGTM) α -amylases). WO 96/23874 further describes methodology for designing, on the basis of an analysis of the structure of a parent Termamyl-like α -amylase, variants of the parent Termamyl-like α -amylase which exhibit altered properties relative to the parent.

BRIEF DISCLOSURE OF THE INVENTION

[0006] The present invention relates to novel α -amylolytic variants (mutants) of a Termamyl-like α -amylase which exhibit improved wash performance (relative to the parent α -amylase) at high pH and at a medium temperature.

[0007] The term "medium temperature" means in the context of the invention a temperature from 10° C. to 60° C., preferably 20° C. to 50° C., especially 30-40° C.

[0008] The term "high pH" means the alkaline pH which today are used for washing, more specifically from about pH 8 to 10.5.

[0009] In the context of the invention a "low temperature α -amylase" means an α -amylase which has an relative optimum activity in the temperature range from 0-30° C.

[0010] In the context of the invention a "medium temperature α -amylase" means an α -amylase which has an optimum activity in the temperature range from 30-60° C. For instance, SP690 and SP722 α -amylases, respectively, are "medium temperature α -amylases."

[0011] In the context of the invention a "high temperature α -amylase" is an α -amylase having the optimum activity in the temperature range from 60-110° C. For instance, Termamyl is a "high temperature α -amylase."

[0012] Alterations in properties which may be achieved in variants (mutants) of the invention are alterations in:

the stability of the Termamyl-like α -amylase at a pH from 8 to 10.5, and/or the Ca²⁺ stability at pH 8 to 10.5, and/or the specific activity at temperatures from 10 to 60° C., preferably 20-50° C., especially 30-40° C.

[0013] It should be noted that the relative temperature optimum often is dependent on the specific pH used. In other words the relative temperature optimum determined at, e.g., pH 8 may be substantially different from the relative temperature optimum determined at, e.g., pH 10.

The Temperature's Influence on the Enzymatic Activity

[0014] The dynamics in the active site and surroundings are dependent on the temperature and the amino acid composition and of strong importance for the relative temperature optimum of an enzyme. By comparing the dynamics of medium and high temperature α -amylases, regions of importance for the function of high temperature α -amylases at medium temperatures can be determined. The temperature activity profile of the SP722 α -amylase (SEQ ID NO: 2) and the *B. licheniformis* α -amylase (available from Novo Nordisk as Termamyl®) (SEQ ID NO: 4) are shown in FIG. 2.

[0015] The relative temperature optimum of SP722 in absolute activities are shown to be higher at medium range temperatures (30-60° C.) than the homologous *B. licheniformis* α -amylase, which have an optimum activity around 60-100° C. The profiles are mainly dependent on the temperature stability and the dynamics of the active site residues and their surroundings. Further, the activity profiles are dependent on the pH used and the pKa of the active site residues.

[0016] In the first aspect the invention relates to a variant of a parent Termamyl-like α -amylase, which variant has α -amylase activity, said variant comprises one or more mutations corresponding to the following mutations in the amino acid sequence shown in SEQ ID NO: 2:

T141, K142, F143, D144, F145, P146, G147, R148, G149, Q174, R181, G182, D183, G184, K185, A186, W189, S193, N195, H107, K108, G109, D166, W167, D168, Q169, S170, R171, Q172, F173, F267, W268, K269, N270, D271, L272, G273, A274, L275, K311, E346, K385, G456, N457, K458, P459, G460, T461, V462, T463.

[0017] A variant of the invention have one or more of the following substitutions or deletions:

T141A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,W,Y,V;
 K142A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;
 F143A,D,R,N,C,E,Q,G,H,I,L,K,M,P,S,T,W,Y,V;
 D144A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 F145A,D,R,N,C,E,Q,G,H,I,L,K,M,P,S,T,W,Y,V;
 P146A,D,R,N,C,E,Q,G,H,I,L,K,M,F,S,T,W,Y,V;
 G147A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 R148A,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 G149A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;
 R181*,A,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 G182*,A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;
 D183*,A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 G184*,A,R,D,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;
 K185A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;
 A186D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 W189A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,Y,V;
 S193A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,T,W,Y,V;
 N195A,D,R,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 H107A,D,R,N,C,E,Q,G,I,L,K,M,F,P,S,T,W,Y,V;
 K108A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;
 G109A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;
 D166A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 W167A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,Y,V;
 D168A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 Q169A,D,R,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 S170A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,T,W,Y,V;
 R171A,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 Q172A,D,R,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 F173A,D,R,N,C,E,Q,G,H,I,L,K,M,P,S,T,W,Y,V;
 Q174*,A,D,R,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 F267A,D,R,N,C,E,Q,G,H,I,L,K,M,P,S,T,W,Y,V;
 W268A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,Y,V;

K269A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;
 N270A,D,R,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 D271A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 L272A,D,R,N,C,E,Q,G,H,I,K,M,F,P,S,T,W,Y,V;
 G273A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;
 A274D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 L275A,D,R,N,C,E,Q,G,H,I,K,M,F,P,S,T,W,Y,V;
 K311A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;
 E346A,D,R,N,C,Q,G,H,I,K,L,M,F,P,S,T,W,Y,V;
 K385A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;
 G456A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;
 N457A,D,R,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
 K458A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;
 P459A,D,R,N,C,E,Q,G,H,I,L,K,M,F,S,T,W,Y,V;
 G460A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;
 T461A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,W,Y,V;
 V462A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y;
 T463A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,W,Y,V.

[0018] Preferred are variants having one or more of the following substitutions or deletions:

K142R; S193P; N195F; K269R,Q; N270Y,R,D; K311R;
 E346Q; K385R; K458R; P459T; T461P; Q174*;
 R181Q,N,S; G182T,S,N; D183*; G184*;
 K185A,R,D,C,E,Q,G,H,I,L,M,N,F,P,S,T,W,Y,V;
 A186T,S,N,I,V,R; W189T,S,N,Q.

[0019] Especially preferred are variants having a deletion in positions D183 and G184 and further one or more of the following substitutions or deletions:

K142R; S193P; N195F; K269R,Q; N270Y,R,D; K311R;
 E346Q; K385R; K458R; P459T; T461P; Q174*;
 R181Q,N,S; G182T,S,N;
 K185A,R,D,C,E,Q,G,H,I,L,M,N,F,P,S,T,W,Y,V;
 A186T,S,N,I,V,R; W189T,S,N,Q.

[0020] The variants of the invention mentioned above exhibits an alteration in at least one of the following properties relative to the parent α -amylase:

i) improved pH stability at a pH from 8 to 10.5; and/or
 ii) improved Ca^{2+} stability at pH 8 to 10.5, and/or
 iii) increased specific activity at temperatures from 10 to 60° C., preferably 20-50° C., especially 30-40° C. Further, details will be described below.

[0021] The invention further relates to DNA constructs encoding variants of the invention; to methods for preparing variants of the invention; and to the use of variants of the

invention, alone or in combination with other enzymes, in various industrial products or processes, e.g., in detergents or for starch liquefaction.

[0022] In a final aspect the invention relates to a method of providing α -amylases with altered pH optimum, and/or altered temperature optimum, and/or improved stability.

Nomenclature

[0023] In the present description and claims, the conventional one-letter and three-letter codes for amino acid residues are used. For ease of reference, α -amylase variants of the invention are described by use of the following nomenclature:

Original amino acid(s):position(s):substituted amino acid(s)

[0024] According to this nomenclature, for instance the substitution of alanine for asparagine in position 30 is shown as:

[0025] Ala30Asn or A30N

a deletion of alanine in the same position is shown as:

[0026] Ala30* or A30*

and insertion of an additional amino acid residue, such as lysine, is shown as:

[0027] Ala30AlaLys or A30AK

[0028] A deletion of a consecutive stretch of amino acid residues, such as amino acid residues 30-33, is indicated as (30-33)* or Δ (A30-N33).

[0029] Where a specific α -amylase contains a “deletion” in comparison with other α -amylases and an insertion is made in such a position this is indicated as:

[0030] *36Asp or *36D

for insertion of an aspartic acid in position 36

Multiple mutations are separated by plus signs, i.e.:

[0031] Ala30Asp+Glu34Ser or A30N+E34S

representing mutations in positions 30 and 34 substituting alanine and glutamic acid for asparagine and serine, respectively.

[0032] When one or more alternative amino acid residues may be inserted in a given position it is indicated as

[0033] A30N,E or

[0034] A30N or A30E

[0035] Furthermore, when a position suitable for modification is identified herein without any specific modification being suggested, it is to be understood that any amino acid residue may be substituted for the amino acid residue present in the position.

[0036] Thus, for instance, when a modification of an alanine in position 30 is mentioned, but not specified, it is to be understood that the alanine may be deleted or substituted for any other amino acid, i.e., any one of:

R,N,D,A,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V.

BRIEF DESCRIPTION OF THE DRAWING

[0037] FIGS. 1 (a)-(c) is an alignment of the amino acid sequences of six parent Termamyl-like α -amylases. The numbers on the extreme left designate the respective amino acid sequences as follows:

1: SEQ ID NO: 2

2: Kaoamyl

3: SEQ ID NO: 1

4: SEQ ID NO: 5

5: SEQ ID NO: 4

6: SEQ ID NO: 3.

[0038] FIG. 2 shows the temperature activity profile of SP722 (SEQ ID NO: 2) (at pH 9) and *B. licheniformis* α -amylase (SEQ ID NO: 4) (at pH 7.3).

[0039] FIG. 3 shows the temperature profile for SP690 (SEQ ID NO: 1), SP722 (SEQ ID NO: 2), *B. licheniformis* α -amylase (SEQ ID NO: 4) at pH 10.

[0040] FIGS. 4(a)-(b) is an alignment of the amino acid sequences of five α -amylases. The numbers on the extreme left designate the respective amino acid sequences as follows:

1: amyp_mouse

2: amyp_rat

3: amyp_pig porcine pancreatic alpha-amylase (PPA)

4: amyp_human

5: amy_altha *A. haloplanctis* alpha-amylase (AHA)

DETAILED DISCLOSURE OF THE INVENTION

The Termamyl-Like α -Amylase

[0041] It is well known that a number of α -amylases produced by *Bacillus* spp. are highly homologous on the amino acid level. For instance, the *B. licheniformis* α -amylase comprising the amino acid sequence shown in SEQ ID NO: 4 (commercially available as Termamyl™) has been found to be about 89% homologous with the *B. amyloliquefaciens* α -amylase comprising the amino acid sequence shown in SEQ ID NO: 5 and about 79% homologous with the *B. stearo-thermophilus* α -amylase comprising the amino acid sequence shown in SEQ ID NO: 3. Further homologous α -amylases include an α -amylase derived from a strain of the *Bacillus* sp. NCIB 12289, NCIB 12512, NCIB 12513 or DSM 9375, all of which are described in detail in WO 95/26397, and the α -amylase described by Tsukamoto et al., Biochemical and Biophysical Research Communications, 151 (1988), pp. 25-31, (see SEQ ID NO: 6).

[0042] Still further homologous α -amylases include the α -amylase produced by the *B. licheniformis* strain described in EP 0252666 (ATCC 27811), and the α -amylases identified in WO 91/00353 and WO 94/18314. Other commercial Termamyl-like *B. licheniformis* α -amylases are comprised in the products Optitherm™ and Takatherm™ (available from Solvay), Maxamyl™ (available from Gist-brocades/Genencor), Spezym AA™ and Spezyme Delta AA™ (available from Genencor), and Keistase™ (available from Daiwa).

[0043] Because of the substantial homology found between these α -amylases, they are considered to belong to the same class of α -amylases, namely the class of “Termamyl-like α -amylases”.

[0044] Accordingly, in the present context, the term “Termamyl-like α -amylase” is intended to indicate an α -amylase which, at the amino acid level, exhibits a substantial homology to Termamyl™, i.e., the *B. licheniformis* α -amylase having the amino acid sequence shown in SEQ ID NO:4 herein. In other words, all the following α -amylases which has the

amino acid sequences shown in SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7 or 8 herein, or the amino acid sequence shown in SEQ ID NO: 1 of WO 95/26397 (the same as the amino acid sequence shown as SEQ ID NO: 7 herein) or in SEQ ID NO: 2 of WO 95/26397 (the same as the amino acid sequence shown as SEQ ID NO: 8 herein) or in Tsukamoto et al., 1988, (which amino acid sequence is shown in SEQ ID NO: 6 herein) are considered to be "Termamyl-like α -amylase". Other Termamyl-like α -amylases are α -amylases i) which displays at least 60%, such as at least 70%, e.g., at least 75%, or at least 80%, e.g., at least 85%, at least 90% or at least 95% homology with at least one of said amino acid sequences shown in SEQ ID NOS: 1-8 and/or ii) displays immunological cross-reactivity with an antibody raised against at least one of said α -amylases, and/or iii) is encoded by a DNA sequence which hybridizes to the DNA sequences encoding the above-specified α -amylases which are apparent from SEQ ID NOS: 9, 10, 11, or 12 of the present application (which encoding sequences encode the amino acid sequences shown in SEQ ID NOS: 1, 2, 3, 4 and 5 herein, respectively), from SEQ ID NO: 4 of WO 95/26397 (which DNA sequence, together with the stop codon TAA, is shown in SEQ ID NO: 13 herein and encodes the amino acid sequence shown in SEQ ID NO: 8 herein) and from SEQ ID NO: 5 of WO 95/26397 (shown in SEQ ID NO: 14 herein), respectively.

[0045] In connection with property i), the "homology" may be determined by use of any conventional algorithm, preferably by use of the GAP programme from the GCG package version 7.3 (June 1993) using default values for GAP penalties, which is a GAP creation penalty of 3.0 and GAP extension penalty of 0.1, (Genetic Computer Group (1991) Programme Manual for the GCG Package, version 7, 575 Science Drive, Madison, Wis., USA 53711).

[0046] A structural alignment between Termamyl (SEQ ID NO: 4) and a Termamyl-like α -amylase may be used to identify equivalent/corresponding positions in other Termamyl-like α -amylases. One method of obtaining said structural alignment is to use the Pile Up programme from the GCG package using default values of gap penalties, i.e., a gap creation penalty of 3.0 and gap extension penalty of 0.1. Other structural alignment methods include the hydrophobic cluster analysis (Gaboriaud et al., (1987), FEBS LETTERS 224, pp. 149-155) and reverse threading (Huber, T; Torda, A E, PROTEIN SCIENCE Vol. 7, No. 1 pp. 142-149 (1998)).

[0047] Property ii) of the α -amylase, i.e., the immunological cross reactivity, may be assayed using an antibody raised against, or reactive with, at least one epitope of the relevant Termamyl-like α -amylase. The antibody, which may either be monoclonal or poly-clonal, may be produced by methods known in the art, e.g., as described by Hudson et al., Practical Immunology, Third edition (1989), Blackwell Scientific Publications. The immunological cross-reactivity may be determined using assays known in the art, examples of which are Western Blotting or radial immunodiffusion assay, e.g., as described by Hudson et al., 1989. In this respect, immunological cross-reactivity between the α -amylases having the amino acid sequences SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, or 8, respectively, has been found.

[0048] The oligonucleotide probe used in the characterisation of the Termamyl-like α -amylase in accordance with property iii) above may suitably be prepared on the basis of the full or partial nucleotide or amino acid sequence of the α -amylase in question.

[0049] Suitable conditions for testing hybridisation involve pre-soaking in 5×SSC and prehybridizing for 1 hour at -40° C. in a solution of 20% formamide, 5×Denhardt's solution, 50 mM sodium phosphate, pH 6.8, and 50 mg of denatured sonicated calf thymus DNA, followed by hybridisation in the same solution supplemented with 100 mM ATP for 18 hours at -40° C., followed by three times washing of the filter in 2×SSC, 0.2% SDS at 40° C. for 30 minutes (low stringency), preferred at 50° C. (medium stringency), more preferably at 65° C. (high stringency), even more preferably at -75° C. (very high stringency). More details about the hybridisation method can be found in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989.

[0050] In the present context, "derived from" is intended not only to indicate an α -amylase produced or producible by a strain of the organism in question, but also an α -amylase encoded by a DNA sequence isolated from such strain and produced in a host organism transformed with said DNA sequence. Finally, the term is intended to indicate an α -amylase which is encoded by a DNA sequence of synthetic and/or cDNA origin and which has the identifying characteristics of the α -amylase in question. The term is also intended to indicate that the parent α -amylase may be a variant of a naturally occurring α -amylase, i.e. a variant which is the result of a modification (insertion, substitution, deletion) of one or more amino acid residues of the naturally occurring α -amylase.

Parent Hybrid α -Amylases

[0051] The parent α -amylase (i.e., backbone α -amylase) may be a hybrid α -amylase, i.e., an α -amylase which comprises a combination of partial amino acid sequences derived from at least two α -amylases.

[0052] The parent hybrid α -amylase may be one which on the basis of amino acid homology and/or immunological cross-reactivity and/or DNA hybridization (as defined above) can be determined to belong to the Termamyl-like α -amylase family. In this case, the hybrid α -amylase is typically composed of at least one part of a Termamyl-like α -amylase and part(s) of one or more other α -amylases selected from Termamyl-like α -amylases or non-Termamyl-like α -amylases of microbial (bacterial or fungal) and/or mammalian origin.

[0053] Thus, the parent hybrid α -amylase may comprise a combination of partial amino acid sequences deriving from at least two Termamyl-like α -amylases, or from at least one Termamyl-like and at least one non-Termamyl-like bacterial α -amylase, or from at least one Termamyl-like and at least one fungal α -amylase. The Termamyl-like α -amylase from which a partial amino acid sequence derives may, e.g., be any of those specific Termamyl-like α -amylase referred to herein.

[0054] For instance, the parent α -amylase may comprise a C-terminal part of an α -amylase derived from a strain of *B. licheniformis*, and a N-terminal part of an α -amylase derived from a strain of *B. amyloliquefaciens* or from a strain of *B. stearotheophilus*. For instance, the parent α -amylase may comprise at least 430 amino acid residues of the C-terminal part of the *B. licheniformis* α -amylase, and may, e.g., comprise a) an amino acid segment corresponding to the 37 N-terminal amino acid residues of the *B. amyloliquefaciens* α -amylase having the amino acid sequence shown in SEQ ID NO: 5 and an amino acid segment corresponding to the 445 C-terminal amino acid residues of the *B. licheniformis* α -amylase having the amino acid sequence shown in SEQ ID NO: 4, or

a hybrid Termamyl-like α -amylase being identical to the Termamyl sequence, i.e., the *Bacillus licheniformis* α -amylase shown in SEQ ID NO: 4, except that the N-terminal 35 amino acid residues (of the mature protein) has been replaced by the N-terminal 33 residues of BAN (mature protein), i.e., the *Bacillus amyloliquefaciens* α -amylase shown in SEQ ID NO: 5; or b) an amino acid segment corresponding to the 68 N-terminal amino acid residues of the *B. stearothermophilus* α -amylase having the amino acid sequence shown in SEQ ID NO: 3 and an amino acid segment corresponding to the 415 C-terminal amino acid residues of the *B. licheniformis* α -amylase having the amino acid sequence shown in SEQ ID NO: 4.

[0055] Another suitable parent hybrid α -amylase is the one previously described in WO 96/23874 (from Novo Nordisk) constituting the N-terminus of BAN, *Bacillus amyloliquefaciens* α -amylase (amino acids 1-300 of the mature protein) and the C-terminus from Termamyl (amino acids 301-483 of the mature protein). Increased activity was achieved by substituting one or more of the following positions of the above hybrid α -amylase (BAN:1-300/Termamyl:301-483): Q360, F290, and N102. Particularly interesting substitutions are one or more of the following substitutions: Q360E,D; F290A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T; N102D,E;

[0056] The corresponding positions in the SP722 α -amylase shown in SEQ ID NO: 2 are one or more of: 5365, Y295, N106. Corresponding substitutions of particular interest in said α -amylase shown in SEQ ID NO: 2 are one or more of: S365D,E; Y295 A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T; and N106D,E.

[0057] The corresponding positions in the SP690 α -amylase shown in SEQ ID NO: 1 are one or more of: 5365, Y295, N106. The corresponding substitutions of particular interest are one or more of: S365D,E; Y295 A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T; N106D,E.

[0058] The above mentioned non-Termamyl-like α -amylase may, e.g., be a fungal α -amylase, a mammalian or a plant α -amylase or a bacterial α -amylase (different from a Termamyl-like α -amylase). Specific examples of such α -amylases include the *Aspergillus oryzae* TAKA α -amylase, the *A. niger* acid α -amylase, the *Bacillus subtilis* α -amylase, the porcine pancreatic α -amylase and a barley α -amylase. All of these α -amylases have elucidated structures which are markedly different from the structure of a typical Termamyl-like α -amylase as referred to herein.

[0059] The fungal α -amylases mentioned above, i.e., derived from *A. niger* and *A. oryzae*, are highly homologous on the amino acid level and generally considered to belong to the same family of α -amylases. The fungal α -amylase derived from *Aspergillus oryzae* is commercially available under the tradename Fungamyl™.

[0060] Furthermore, when a particular variant of a Termamyl-like α -amylase (variant of the invention) is referred to—in a conventional manner—by reference to modification (e.g., deletion or substitution) of specific amino acid residues in the amino acid sequence of a specific Termamyl-like α -amylase, it is to be understood that variants of another Termamyl-like α -amylase modified in the equivalent position (s) (as determined from the best possible amino acid sequence alignment between the respective amino acid sequences) are encompassed thereby.

[0061] In a preferred embodiment of the invention the α -amylase backbone is derived from *B. licheniformis* (as the parent Termamyl-like α -amylase), e.g., one of those referred

to above, such as the *B. licheniformis* α -amylase having the amino acid sequence shown in SEQ ID NO: 4.

Altered Properties of Variants of the Invention

[0062] The following discusses the relationship between mutations which are present in variants of the invention, and desirable alterations in properties (relative to those a parent Termamyl-like α -amylase) which may result therefrom.

Improved Stability at pH 8-10.5

[0063] In the context of the present invention, mutations (including amino acid substitutions) of importance with respect to achieving improved stability at high pH (i.e., pH 8-10.5) include mutations corresponding to mutations in one or more of the following positions in SP722 α -amylase (having the amino acid sequence shown in SEQ ID NO: 2): T141, K142, F143, D144, F145, P146, G147, R148, G149, R181, A186, 5193, N195, K269, N270, K311, K458, P459, T461.

[0064] The variant of the invention have one or more of the following substitutions (using the SEQ ID NO: 2 numbering):

T141A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,W,Y,V;

K142A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;

F143A,D,R,N,C,E,Q,G,H,I,L,K,M,P,S,T,W,Y,V;

D144A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

F145A,D,R,N,C,E,Q,G,H,I,L,K,M,P,S,T,W,Y,V;

P146A,D,R,N,C,E,Q,G,H,I,L,K,M,F,S,T,W,Y,V;

G147A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;

R148A,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

G149A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;

K181A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;

A186D,R,N,C,E,Q,G,H,I,L,P,K,M,F,S,T,W,Y,V;

S193A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,T,W,Y,V;

N195A,D,R,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

K269A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;

N270A,D,R,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

K311A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;

K458A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;

P459A,D,R,N,C,E,Q,G,H,I,L,K,M,F,S,T,W,Y,V;

T461A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,W,Y,V.

[0065] Preferred high pH stability variants include one or more of the following substitutions in the SP722 α -amylase (having the amino acid sequence shown in SEQ ID NO: 2):

K142R, R181S, A186T, S193P, N195F, K269R, N270Y, K311R, K458R, P459T and T461P.

[0066] In specific embodiments the *Bacillus* strain NCIB 12512 α -amylase having the sequence shown in SEQ ID NO: 1, or the *B. stearothermophilus* α -amylase having the sequence shown in SEQ ID NO: 3, or the *B. licheniformis* α -amylase having the sequence shown in SEQ ID NO: 4, or the *B. amyloliquefaciens* α -amylase having the sequence shown in SEQ ID NO: 5 is used as the backbone, i.e., parent Termamyl-like α -amylase, for these mutations.

[0067] As can be seen from the alignment in FIG. 1 the *B. stearothermophilus* α -amylase already has a Tyrosine at position corresponding to N270 in SP722. Further, the *Bacillus* strain NCIB 12512 α -amylase, the *B. stearothermophilus* α -amylase, the *B. licheniformis* α -amylase and the *B. amyloliquefaciens* α -amylase already have Arginine at position corresponding to K458 in SP722. Furthermore, the *B. licheniformis* α -amylase already has a Proline at position corresponding to T461 in SP722. Therefore, for said α -amylases these substitutions are not relevant.

[0068] α -amylase variants with improved stability at high pH can be constructed by making substitutions in the regions found using the molecular dynamics simulation mentioned in Example 2. The simulation depicts the region(s) that has a higher flexibility or mobility at high pH (i.e., pH 8-10.5) when compared to medium pH.

[0069] By using the structure of any bacterial alpha-amylase with homology (as defined below) to the Termamyl-like α -amylase (BA2), of which the 3D structure is disclosed in Appendix 1 of WO 96/23874 (from Novo Nordisk), it is possible to modelbuild the structure of such alpha-amylase and to subject it to molecular dynamics simulations. The homology of said bacterial α -amylase may be at least 60%, preferably be more than 70%, more preferably more than 80%, most preferably more than 90% homologous to the above mentioned Termamyl-like α -amylase (BA2), measured using the UWGCG GAP program from the GCG package version 7.3 (June 1993) using default values for GAP penalties [Genetic Computer Group (1991) Programme Manual for the GCG Package, version 7, 575 Science Drive, Madison, Wis., USA 53711]. Substitution of the unfavorable residue for another would be applicable.

Improved Ca²⁺ Stability at pH 8-10.5

[0070] Improved Ca²⁺ stability means the stability of the enzyme under Ca²⁺ depletion has been improved. In the context of the present invention, mutations (including amino acid substitutions) of importance with respect to achieving improved Ca²⁺ stability at high pH include mutation or deletion in one or more positions corresponding to the following positions in the SP722 α -amylase having the amino acid sequence shown in SEQ ID NO: 2: R181, G182, D183, G184, K185, A186, W189, N195, N270, E346, K385, K458, P459.

[0071] A variant of the invention have one or more of the following substitutions or deletions:

R181*, A,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

G182*, A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;

D183*, A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

G184*, A,R,D,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;

K185A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;

A186D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

W189A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,Y,V;

N195A,D,R,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

N270A,R,D,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;

E346A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

K385A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;

K458A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;

P459A,R,D,N,C,E,Q,G,H,I,L,K,M,F,S,T,W,Y,V.

[0072] Preferred are variants having one or more of the following substitutions or deletions:

R181Q,N; G182T,S,N; D183*; G184*;
K185A,R,D,C,E,Q,G,H,I,L,M,N,F,P,S,T,W,Y,V;
A186T,S,N,I,V; W189T,S,N,Q; N195F, N270R,D; E346Q;
K385R; K458R; P459T.

[0073] In specific embodiments the *Bacillus* strain NCIB 12512 α -amylase having the sequence shown in SEQ ID NO: 1, or the *B. amyloliquefaciens* α -amylase having the sequence shown in SEQ ID NO: 5, or the *B. licheniformis* α -amylase having the sequence shown in SEQ ID NO: 4 are used as the backbone for these mutations.

[0074] As can be seen from the alignment in FIG. 1 the *B. licheniformis* α -amylase does not have the positions corresponding to D183 and G184 in SP722. Therefore for said α -amylases these deletions are not relevant.

[0075] In a preferred embodiment the variant is the *Bacillus* strain NCIB 12512 α -amylase with deletions in D183 and G184 and further one of the following substitutions: R181Q,N and/or G182T,S,N and/or D183*; G184* and/or K185A,R,D,C,E,Q,G,H,I,L,M,N,F,P,S,T,W,Y,V and/or A186T,S,N,I,V and/or W189T,S,N,Q and/or N195F and/or N270R,D and/or E346Q and/or K385R and/or K458R and/or P459T.

Increased Specific Activity at Medium Temperature

[0076] In a further aspect of the present invention, important mutations with respect to obtaining variants exhibiting increased specific activity at temperatures from 10-60° C., preferably 20-50° C., especially 30-40° C., include mutations corresponding to one or more of the following positions in the SP722 α -amylase having the amino acid sequence shown in SEQ ID NO: 2:

H107, K108, G109, D166, W167, D168, Q169, 5170, R171, Q172, F173, Q174, D183, G184, N195, F267, W268, K269,

N270, D271, L272, G273, A274, L275, G456, N457, K458, P459, G460, T461, V462, T463.

[0077] The variant of the invention have one or more of the following substitutions:

H107A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

K108A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;

G109A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;

D166A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

W167A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,Y,V;

D168A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

Q169A,D,R,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V;

S170A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,T,W,Y,V;

R171A,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

Q172A,D,R,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V;

F173A,D,R,N,C,E,Q,G,H,I,L,K,M,P,S,T,W,Y,V;

Q174*,A,D,R,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V;

D183*,A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,W,Y,V;

G184*,A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

N195A,D,R,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

F267A,D,R,N,C,E,Q,G,H,I,L,K,M,P,S,T,W,Y,V;

W268A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,Y,V;

K269A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;

N270A,D,R,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

D271A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

L272A,D,R,N,C,E,Q,G,H,I,K,M,F,P,S,T,W,Y,V;

G273A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;

A274D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

L275A,D,R,N,C,E,Q,G,H,I,K,M,F,P,S,T,W,Y,V;

G456A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;

N457A,D,R,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;

K458A,D,R,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;

P459A,D,R,N,C,E,Q,G,H,I,L,K,M,F,S,T,W,Y,V;

G460A,D,R,N,C,E,Q,H,I,L,K,M,F,P,S,T,W,Y,V;

T461A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,W,Y,V;

V462A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y;

T463A,D,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,W,Y,V.

[0078] Preferred variants has one or more of the following substitutions or deletions: Q174*, D183*, G184*, K269S.

[0079] In a specific embodiment the *B. licheniformis* α -amylase having the sequence shown in SEQ ID NO: 4 is used as the backbone for these mutations.

General Mutations in Variants of the Invention: Increased Specific Activity at Medium Temperatures

[0080] The particularly interesting amino acid substitution are those that increase the mobility around the active site of the enzyme. This is accomplished by changes that disrupt stabilizing interaction in the vicinity of the active site, i.e., within preferably 10 Å or 8 Å or 6 Å or 4 Å from any of the residues constituting the active site.

[0081] Examples are mutations that reduce the size of side chains, such as

Ala to Gly,

Val to Ala or Gly,

Ile or Leu to Val, Ala, or Gly

Thr to Ser

[0082] Such mutations are expected to cause increased flexibility in the active site region either by the introduction of cavities or by the structural rearrangements that fill the space left by the mutation.

[0083] It may be preferred that a variant of the invention comprises one or more modifications in addition to those outlined above. Thus, it may be advantageous that one or more Proline residues present in the part of the α -amylase variant which is modified is/are replaced with a non-Proline residue which may be any of the possible, naturally occurring non-Proline residues, and which preferably is an Alanine, Glycine, Serine, Threonine, Valine or Leucine.

[0084] Analogously, it may be preferred that one or more Cysteine residues present among the amino acid residues with which the parent α -amylase is modified is/are replaced with a non-Cysteine residue such as Serine, Alanine, Threonine, Glycine, Valine or Leucine.

[0085] Furthermore, a variant of the invention may—either as the only modification or in combination with any of the above outlined modifications—be modified so that one or more Asp and/or Glu present in an amino acid fragment corresponding to the amino acid fragment 185-209 of SEQ ID NO: 4 is replaced by an Asn and/or Gln, respectively. Also of interest is the replacement, in the Termamyl-like α -amylase, of one or more of the Lys residues present in an amino acid fragment corresponding to the amino acid fragment 185-209 of SEQ ID NO: 4 by an Arg.

[0086] It will be understood that the present invention encompasses variants incorporating two or more of the above outlined modifications.

[0087] Furthermore, it may be advantageous to introduce point-mutations in any of the variants described herein.

α -Amylase Variants Having Increased Mobility Around the Active Site:

[0088] The mobility of α -amylase variants of the invention may be increased by replacing one or more amino acid residue at one or more positions close to the substrate site. These positions are (using the SP722 α -amylase (SEQ ID NO: 2) numbering): V56, K108, D168, Q169, Q172, L201, K269, L272, L275, K446, P459.

[0089] Therefore, in an aspect the invention relates to variants being mutated in one or more of the above mentioned positions.

[0090] Preferred substitutions are one or more of the following:

V56A, G, S, T;

K108A,D,E,Q,G,H,I,L,M,N,S,T,V;

D168A,G,I,V,N,S,T;

Q169A,D,G,H,I,L,M,N,S,T,V;

Q172A,D,G,H,I,L,M,N,S,T,V;

L201A,G,I,V,S,T;

K269A,D,E,Q,G,H,I,L,M,N,S,T,V;

L272A,G,I,V,S,T;

L275A,G,I,V,S,T;

Y295A,D,E,Q,G,H,I,L,M,N,F,S,T,V;

K446A,D,E,Q,G,H,I,L,M,N,S,T,V;

P459A,G,I,L,S,T,V.

[0091] In specific embodiments of the invention the *Bacillus* strain NCIB 12512 α -amylase having the sequence shown in SEQ ID NO: 1, or the *B. stearothermophilus* α -amylase having the sequence shown in SEQ ID NO: 3, or the *B. licheniformis* α -amylase having the sequence shown in SEQ ID NO: 4, or the *B. amyloliquefaciens* α -amylase having the sequence shown in SEQ ID NO: 5 are used as the backbone for these mutations.

[0092] As can be seen from the alignment in FIG. 1 the *B. licheniformis* α -amylase and the *B. amyloliquefaciens* α -amylase have a Glutamine at position corresponding to K269 in SP722. Further, the *B. stearothermophilus* α -amylase has a Serine at position corresponding to K269 in SP722. Therefore, for said α -amylases these substitutions are not relevant.

[0093] Furthermore, as can be seen from the alignment in FIG. 1 the *B. amyloliquefaciens* α -amylase has an Alanine at position corresponding to L272 in SP722, and the *B. stearothermophilus* α -amylase has a Isoleucine at the position corresponding to L272 in SP722. Therefore, for said α -amylases these substitutions are not relevant.

[0094] As can be seen from the alignment in FIG. 1, the *Bacillus* strain 12512 α -amylase has a Isoleucine at position corresponding to L275 in SP722. Therefore for said α -amylase this substitution is not relevant.

[0095] As can be seen from the alignment in FIG. 1 the *B. amyloliquefaciens* α -amylase has a Phenylalanine at position corresponding to Y295 in SP722. Further, the *B. stearothermophilus* α -amylase has an Asparagine at position corresponding to Y295 in SP722. Therefore, for said α -amylases these substitutions are not relevant.

[0096] As can be seen from the alignment in FIG. 1 the *B. licheniformis* α -amylase and the *B. amyloliquefaciens* α -amylase have a Asparagine at position corresponding to K446 in SP722. Further, the *B. stearothermophilus* α -amy-

lase has a Histidine at position corresponding to K446 in SP722. Therefore, for said α -amylases these substitutions are not relevant.

[0097] As can be seen from the alignment in FIG. 1 the *B. licheniformis* α -amylase, the *B. amyloliquefaciens* α -amylase and the *B. stearothermophilus* α -amylase have a Serine at position corresponding to P459 in SP722. Further, the *Bacillus* strain 12512 α -amylase has a Threonine at position corresponding to P459 in SP722. Therefore, for said α -amylases these substitutions are not relevant.

Stabilization of Enzymes Having High Activity at Medium Temperatures

[0098] In a further embodiment the invention relates to improving the stability of low temperature α -amylases (e.g., *Alteromonas haloplanctis* (Feller et al., (1994), Eur. J. Biochem 222:441-447), and medium temperature α -amylases (e.g., SP722 and SP690) possessing medium temperature activity, i.e., commonly known as psychrophilic enzymes and mesophilic enzymes. The stability can for this particular enzyme class be understood either as thermostability or the stability at Calcium depletion conditions.

[0099] Typically, enzymes displaying the high activity at medium temperatures also display severe problems under conditions that stress the enzyme, such as temperature or Calcium depletion.

[0100] Consequently, the objective is to provide enzymes that at the same time display the desired high activity at medium temperatures without losing their activity under slightly stressed conditions.

[0101] The activity of the stabilized variant measured at medium temperatures should preferably be between 100% or more and 50%, and more preferably between 100% or more and 70%, and most preferably between 100% or more and 85% of the original activity at that specific temperature before stabilization of the enzyme and the resulting enzyme should withstand longer incubation at stressed condition than the wild type enzyme.

[0102] Contemplated enzymes include α -amylases of, e.g., bacterial or fungal origin.

[0103] An example of such a low temperature α -amylase is the one isolated from *Alteromonas haloplanctis* (Feller et al., (1994), Eur. J. Biochem 222:441-447). The crystal structure of this alpha-amylase has been solved (Aghajari et al., (1998), Protein Science 7:564-572).

[0104] The *A. haloplanctis* alpha-amylase (5 in alignment shown in FIG. 4) has a homology of approximately 66% to porcine pancreatic alpha-amylase (PPA) (3 in the alignment shown in FIG. 4). The PPA 3D structure is known, and can be obtained from Brookhaven database under the name 10SE or 1DHK. Based on the homology to other more stable alpha amylases, stabilization of "the low temperature highly active enzyme" from *Alteromonas haloplanctis* alpha-amylase, can be obtained and at the same time retaining the desired high activity at medium temperatures.

[0105] FIG. 4 shown a multiple sequence alignments of five α -amylases, including the AHA and the PPA α -amylase. Specific mutations giving increased stability in *Alteromonas haloplanctis* alpha-amylase:

T66P, Q69P, R155P, Q177R, A205P, A232P, L243R, V295P, S315R.

Methods for Preparing α -Amylase Variants

[0106] Several methods for introducing mutations into genes are known in the art. After a brief discussion of the cloning of α -amylase-encoding DNA sequences, methods for generating mutations at specific sites within the α -amylase-encoding sequence will be discussed.

Cloning a DNA Sequence Encoding an α -Amylase
Cloning a DNA Sequence Encoding an α -Amylase
Cloning a DNA Sequence Encoding an α -Amylase
Cloning a DNA Sequence Encoding an α -Amylase
Cloning a DNA Sequence Encoding an α -Amylase
Cloning a DNA Sequence Encoding an α -Amylase
Cloning a DNA Sequence Encoding an α -Amylase
Cloning a DNA Sequence Encoding an α -Amylase

[0107] The DNA sequence encoding a parent α -amylase may be isolated from any cell or microorganism producing the α -amylase in question, using various methods well known in the art. First, a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the α -amylase to be studied. Then, if the amino acid sequence of the α -amylase is known, homologous, labeled oligonucleotide probes may be synthesized and used to identify α -amylase-encoding clones from a genomic library prepared from the organism in question. Alternatively, a labeled oligonucleotide probe containing sequences homologous to a known α -amylase gene could be used as a probe to identify α -amylase-encoding clones, using hybridization and washing conditions of lower stringency.

[0108] Yet another method for identifying α -amylase-encoding clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming α -amylase-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for α -amylase, thereby allowing clones expressing the α -amylase to be identified.

[0109] Alternatively, the DNA sequence encoding the enzyme may be prepared synthetically by established standard methods, e.g., the phosphoroamidite method described by S. L. Beaucage and M. H. Caruthers (1981) or the method described by Matthes et al. (1984). In the phosphoroamidite method, oligonucleotides are synthesized, e.g., in an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.

[0110] Finally, the DNA sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate, the fragments corresponding to various parts of the entire DNA sequence), in accordance with standard techniques. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in U.S. Pat. No. 4,683,202 or R. K. Saiki et al. (1988).

Expression of α -Amylase Variants

[0111] According to the invention, a DNA sequence encoding the variant produced by methods described above, or by any alternative methods known in the art, can be expressed, in enzyme form, using an expression vector which typically includes control sequences encoding a promoter, operator,

ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.

[0112] The recombinant expression vector carrying the DNA sequence encoding an α -amylase variant of the invention may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, a bacteriophage or an extrachromosomal element, minichromosome or an artificial chromosome. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

[0113] In the vector, the DNA sequence should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA sequence encoding an α -amylase variant of the invention, especially in a bacterial host, are the promoter of the lac operon of *E. coli*, the *Streptomyces coelicolor* agarase gene *dagA* promoters, the promoters of the *Bacillus licheniformis* α -amylase gene (*amyL*), the promoters of the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the promoters of the *Bacillus amyloliquefaciens* α -amylase (*amyQ*), the promoters of the *Bacillus subtilis* *xylA* and *xylB* genes etc. For transcription in a fungal host, examples of useful promoters are those derived from the gene encoding *A. oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *A. niger* neutral α -amylase, *A. niger* acid stable α -amylase, *A. niger* glucoamylase, *Rhizomucor miehei* lipase, *A. oryzae* alkaline protease, *A. oryzae* triose phosphate isomerase or *A. nidulans* acetamidase.

[0114] The expression vector of the invention may also comprise a suitable transcription terminator and, in eukaryotes, polyadenylation sequences operably connected to the DNA sequence encoding the α -amylase variant of the invention. Termination and polyadenylation sequences may suitably be derived from the same sources as the promoter.

[0115] The vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pIJ702.

[0116] The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the *dal* genes from *B. subtilis* or *B. licheniformis*, or one which confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance. Furthermore, the vector may comprise *Aspergillus* selection markers such as *amdS*, *argB*, *niaD* and *sC*, a marker giving rise to hygromycin resistance, or the selection may be accomplished by co-transformation, e.g., as described in WO 91/17243.

[0117] While intracellular expression may be advantageous in some respects, e.g., when using certain bacteria as host cells, it is generally preferred that the expression is extracellular. In general, the *Bacillus* α -amylases mentioned herein comprise a preregion permitting secretion of the expressed protease into the culture medium. If desirable, this

preregion may be replaced by a different preregion or signal sequence, conveniently accomplished by substitution of the DNA sequences encoding the respective preregions.

[0118] The procedures used to ligate the DNA construct of the invention encoding an α -amylase variant, the promoter, terminator and other elements, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor, 1989).

[0119] The cell of the invention, either comprising a DNA construct or an expression vector of the invention as defined above, is advantageously used as a host cell in the recombinant production of an α -amylase variant of the invention. The cell may be transformed with the DNA construct of the invention encoding the variant, conveniently by integrating the DNA construct (in one or more copies) in the host chromosome. This integration is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed according to conventional methods, e.g., by homologous or heterologous recombination. Alternatively, the cell may be transformed with an expression vector as described above in connection with the different types of host cells.

[0120] The cell of the invention may be a cell of a higher organism such as a mammal or an insect, but is preferably a microbial cell, e.g. a bacterial or a fungal (including yeast) cell.

[0121] Examples of suitable bacteria are Gram positive bacteria such as *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentos*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus megaterium*, *Bacillus thuringiensis*, or *Streptomyces lividans* or *Streptomyces murinus*, or gramnegative bacteria such as *E. coli*. The transformation of the bacteria may, for instance, be effected by protoplast transformation or by using competent cells in a manner known per se.

[0122] The yeast organism may favorably be selected from a species of *Saccharomyces* or *Schizosaccharomyces*, e.g. *Saccharomyces cerevisiae*. The filamentous fungus may advantageously belong to a species of *Aspergillus*, e.g., *Aspergillus oryzae* or *Aspergillus niger*. Fungal cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known per se. A suitable procedure for transformation of *Aspergillus* host cells is described in EP 238 023.

[0123] In a yet further aspect, the present invention relates to a method of producing an α -amylase variant of the invention, which method comprises cultivating a host cell as described above under conditions conducive to the production of the variant and recovering the variant from the cells and/or culture medium.

[0124] The medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in question and obtaining expression of the α -amylase variant of the invention. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. as described in catalogues of the American Type Culture Collection).

[0125] The α -amylase variant secreted from the host cells may conveniently be recovered from the culture medium by

well-known procedures, including separating the cells from the medium by centrifugation or filtration, and precipitating proteinaceous components of the medium by means of a salt such as ammonium sulphate, followed by the use of chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

INDUSTRIAL APPLICATIONS

[0126] The α -amylase variants of this invention possesses valuable properties allowing for a variety of industrial applications. In particular, enzyme variants of the invention are applicable as a component in washing, dishwashing and hard-surface cleaning detergent compositions.

[0127] Numerous variants are particularly useful in the production of sweeteners and ethanol from starch, and/or for textile desizing. Conditions for conventional starch-conversion processes, including starch liquefaction and/or saccharification processes, are described in, e.g., U.S. Pat. No. 3,912,590 and in EP patent publications Nos. 252,730 and 63,909.

Detergent Compositions

[0128] As mentioned above, variants of the invention may suitably be incorporated in detergent compositions. Reference is made, for example, to WO 96/23874 and WO 97/07202 for further details concerning relevant ingredients of detergent compositions (such as laundry or dishwashing detergents), appropriate methods of formulating the variants in such detergent compositions, and for examples of relevant types of detergent compositions.

[0129] Detergent compositions comprising a variant of the invention may additionally comprise one or more other enzymes, such as a lipase, cutinase, protease, cellulase, peroxidase or laccase, and/or another α -amylase.

[0130] α -amylase variants of the invention may be incorporated in detergents at conventionally employed concentrations. It is at present contemplated that a variant of the invention may be incorporated in an amount corresponding to 0.00001-1 mg (calculated as pure, active enzyme protein) of α -amylase per liter of wash/dishwash liquor using conventional dosing levels of detergent.

[0131] The invention also relates to a method of providing α -amylases with 1) altered pH optimum, and/or 2) altered temperature optimum, and/or 3) improved stability, comprising the following steps:

- i) identifying (a) target position(s) and/or region(s) for mutation of the α -amylase by comparing the molecular dynamics of two or more α -amylase 3D structures having substantially different pH, temperature and/or stability profiles,
- ii) substituting, adding and/or deleting one or more amino acids in the identified position(s) and/or region(s).

[0132] In embodiment of the invention a medium temperature α -amylase is compared with a high temperature α -amylase. In another embodiment a low temperature α -amylase is compared with either a medium or a high temperature α -amylase.

[0133] The α -amylases compared should preferably be at least 70%, preferably 80%, up to 90%, such as up to 95%, especially 95% homologous with each other.

[0134] The α -amylases compared may be Termamyl-like α -amylases as defined above. In specific embodiment the α -amylases compared are the α -amylases shown in SEQ ID NO: 1 to SEQ ID NO: 8.

[0135] In another embodiment the stability profile of the α -amylases in question compared are the Ca^{2+} dependency profile.

Materials and Methods

Enzymes:

[0136] SP722: (SEQ ID NO: 2, available from Novo Nordisk)

Termamyl™ (SEQ ID NO: 4, available from Novo Nordisk)

SP690: (SEQ ID NO: 1, available from Novo Nordisk)

Bacillus subtilis SHA273: see WO 95/10603

Plasmids

[0137] pJE1 contains the gene encoding a variant of SP722 α -amylase (SEQ ID NO: 2): viz. deletion of 6 nucleotides corresponding to amino acids D183-G184 in the mature protein. Transcription of the JE1 gene is directed from the amyL promoter. The plasmid further more contains the origin of replication and cat-gene conferring resistance towards kanamycin obtained from plasmid pUB110 (Gryczan, T J et al. (1978), J. Bact. 134:318-329).

Methods:

[0138] Construction of Library Vector pDorK101

[0139] The *E. coli*/*Bacillus* shuttle vector pDorK101 (described below) can be used to introduce mutations without expression of α -amylase in *E. coli* and then be modified in such way that the α -amylase is active in *Bacillus*. The vector was constructed as follows: The JE1 encoding gene (SP722 with the deletion of D183-G184) was inactivated in pJE1 by gene interruption in the PstI site in the 5' coding region of the SEQ ID NO: 2: SP722 by a 1.2 kb fragment containing an *E. coli* origin of replication. This fragment was PCR amplified from the pUC19 (GenBank Accession #:X02514) using the forward primer: 5'-gacctgcagtcaggcaacta-3' and the reverse primer: 5'-tagatgcgacctgcaggcat-3'. The PCR amplicon and the pJE1 vector were digested with PstI at 37° C. for hours. The pJE1 vector fragment and the PCR fragment were ligated at room temperature. for 1 hour and transformed in *E. coli* by electrotransformation. The resulting vector is designated pDorK101.

Filter Screening Assays

[0140] The assay can be used to screening of Termamyl-like α -amylase variants having an improved stability at high pH compared to the parent enzyme and Termamyl-like α -amylase variants having an improved stability at high pH and medium temperatures compared to the parent enzyme depending of the screening temperature setting

High pH Filter Assay

[0141] *Bacillus* libraries are plated on a sandwich of cellulose acetate (OE 67, Schleicher & Schuell, Dassel, Germany)—and nitrocellulose filters (Protran-Ba 85, Schleicher & Schuell, Dassel, Germany) on TY agar plates with 10 $\mu\text{g}/\text{ml}$ kanamycin at 37° C. for at least 21 hours. The cellulose acetate layer is located on the TY agar plate.

[0142] Each filter sandwich is specifically marked with a needle after plating, but before incubation in order to be able to localize positive variants on the filter and the nitrocellulose filter with bound variants is transferred to a container with

glycin-NaOH buffer, pH 8.6-10.6 and incubated at room temperature (can be altered from 10°-60° C.) for 15 min. The cellulose acetate filters with colonies are stored on the TY-plates at room temperature until use. After incubation, residual activity is detected on plates containing 1% agarose, 0.2% starch in glycin-NaOH buffer, pH 8.6-10.6. The assay plates with nitrocellulose filters are marked the same way as the filter sandwich and incubated for 2 hours. at room temperature. After removal of the filters the assay plates are stained with 10% Lugol solution. Starch degrading variants are detected as white spots on dark blue background and then identified on the storage plates. Positive variants are rescreened twice under the same conditions as the first screen.

Low Calcium Filter Assay

[0143] The *Bacillus* library are plated on a sandwich of cellulose acetate (OE 67, Schleicher & Schuell, Dassel, Germany)—and nitrocellulose filters (Protran-Ba 85, Schleicher & Schuell, Dassel, Germany) on TY agar plates with a relevant antibiotic, e.g., kanamycin or chloramphenicol, at 37° C. for at least 21 hours. The cellulose acetate layer is located on the TY agar plate.

[0144] Each filter sandwich is specifically marked with a needle after plating, but before incubation in order to be able to localize positive variants on the filter and the nitrocellulose filter with bound variants is transferred to a container with carbonate/bicarbonate buffer pH 8.5-10 and with different EDTA concentrations (0.001 mM-100 mM). The filters are incubated at room temperature for 1 hour. The cellulose acetate filters with colonies are stored on the TY-plates at room temperature until use. After incubation, residual activity is detected on plates containing 1% agarose, 0.2% starch in carbonate/bicarbonate buffer pH 8.5-10. The assay plates with nitrocellulose filters are marked the same way as the filter sandwich and incubated for 2 hours. at room temperature. After removal of the filters the assay plates are stained with 10% Lugol solution. Starch degrading variants are detected as white spots on dark blue background and then identified on the storage plates. Positive variants are rescreened twice under the same conditions as the first screen.

Method to Obtaining the Regions of Interest:

[0145] There are three known 3D structures of bacterial α -amylases. Two of *B. licheniformis* α -amylase, Brookhaven database 1BPL (Machius et al. (1995), J. Mol. Biol. 246, p. 545-559) and 1VJS (Song et al. (1996), Enzymes for Carbohydrate 163 Engineering (Prog. Biotechnol. V 12). These two structures are lacking an important piece of the structure from the so-called B-domain, in the area around the two Calcium ions and one Sodium ion binding sites. We have therefore used a 3D structure of an α -amylase BA2 (WO 96/23874 which are a hybrid between BAN™ (SEQ ID NO. 5) and *B. licheniformis* α -amylase (SEQ ID NO. 4). On basis of the structure a model of *B. licheniformis* alpha amylase and the SP722 α -amylase has been build.

Fermentation and Purification of α -Amylase Variants

[0146] Fermentation and purification may be performed by methods well known in the art.

Stability Determination

[0147] All stability trials are made using the same set up. The method are:

The enzyme is incubated under the relevant conditions (1-4). Samples are taken at various time points, e.g., after 0, 5, 10,

and 30 minutes and diluted 25 times (same dilution for all taken samples) in assay buffer (0.1M 50 mM Britton buffer pH 7.3) and the activity is measured using the Phadebas assay (Pharmacia) under standard conditions pH 7.3, 37° C.

[0148] The activity measured before incubation (0 minutes) is used as reference (100%). The decline in percent is calculated as a function of the incubation time. The table shows the residual activity after, e.g., 30 minutes of incubation.

Specific Activity Determination

[0149] The specific activity is determined using the Phadebas assay (Pharmacia) as activity/mg enzyme. The manufacturer instructions are followed (see also below under "Assay for α -amylase activity").

Assays for α -Amylase Activity

1. Phadebas Assay

[0150] α -amylase activity is determined by a method employing Phadebas® tablets as substrate. Phadebas tablets (Phadebas® Amylase Test, supplied by Pharmacia Diagnostic) contain a cross-linked insoluble blue-colored starch polymer which has been mixed with bovine serum albumin and a buffer substance and tableted.

[0151] For every single measurement one tablet is suspended in a tube containing 5 ml 50 mM Britton-Robinson buffer (50 mM acetic acid, 50 mM phosphoric acid, 50 mM boric acid, 0.1 mM CaCl_2 , pH adjusted to the value of interest with NaOH). The test is performed in a water bath at the temperature of interest. The α -amylase to be tested is diluted in x ml of 50 mM Britton-Robinson buffer. 1 ml of this α -amylase solution is added to the 5 ml 50 mM Britton-Robinson buffer. The starch is hydrolyzed by the α -amylase giving soluble blue fragments. The absorbance of the resulting blue solution, measured spectrophotometrically at 620 nm, is a function of the α -amylase activity.

[0152] It is important that the measured 620 nm absorbance after 10 or 15 minutes of incubation (testing time) is in the range of 0.2 to 2.0 absorbance units at 620 nm. In this absorbance range there is linearity between activity and absorbance (Lambert-Beer law). The dilution of the enzyme must therefore be adjusted to fit this criterion. Under a specified set of conditions (temp., pH, reaction time, buffer conditions) 1 mg of a given α -amylase will hydrolyze a certain amount of substrate and a blue colour will be produced. The colour intensity is measured at 620 nm. The measured absorbance is directly proportional to the specific activity (activity/mg of pure α -amylase protein) of the α -amylase in question under the given set of conditions.

2. Alternative Method

[0153] α -amylase activity is determined by a method employing the PNP-G7 substrate. PNP-G7 which is a abbreviation for p-nitrophenyl- α -D-maltoheptaoside is a blocked oligosaccharide which can be cleaved by an endo-amylase. Following the cleavage, the α -Glucosidase included in the kit digest the substrate to liberate a free PNP molecule which has a yellow colour and thus can be measured by visible spectrophotometry at $\lambda=405$ nm. (400-420 nm.). Kits containing PNP-G7 substrate and α -Glucosidase is manufactured by Boehringer-Mannheim (cat. No. 1054635).

[0154] To prepare the substrate one bottle of substrate (BM 1442309) is added to 5 ml buffer (BM1442309). To prepare the α -Glucosidase one bottle of α -Glucosidase (BM 1462309) is added to 45 ml buffer (BM1442309). The working solution is made by mixing 5 ml α -Glucosidase solution with 0.5 ml substrate.

[0155] The assay is performed by transforming 20 μ l enzyme solution to a 96 well microtitre plate and incubating at 25° C. 200 μ l working solution, 25° C. is added. The solution is mixed and pre-incubated 1 minute and absorption is measured every 15 sec. over 3 minutes at OD 405 nm.

[0156] The slope of the time dependent absorption-curve is directly proportional to the specific activity (activity per mg enzyme) of the α -amylase in question under the given set of conditions.

General Method for Random Mutagenesis by Use of the DOPE Program

[0157] The random mutagenesis may be carried out by the following steps:

1. Select regions of interest for modification in the parent enzyme
2. Decide on mutation sites and non-mutated sites in the selected region
3. Decide on which kind of mutations should be carried out, e.g. with respect to the desired stability and/or performance of the variant to be constructed
4. Select structurally reasonable mutations.
5. Adjust the residues selected by step 3 with regard to step 4.
6. Analyze by use of a suitable dope algorithm the nucleotide distribution.
7. If necessary, adjust the wanted residues to genetic code realism (e.g., taking into account constraints resulting from the genetic code (e.g. in order to avoid introduction of stop codons)) (the skilled person will be aware that some codon combinations cannot be used in practice and will need to be adapted)
8. Make primers
9. Perform random mutagenesis by use of the primers
10. Select resulting α -amylase variants by screening for the desired improved properties.

[0158] Suitable dope algorithms for use in step 6 are well known in the art. One algorithm is described by Tomandl, D. et al., Journal of Computer-Aided Molecular Design, 11 (1997), pp. 29-38). Another algorithm, DOPE, is described in the following:

The Dope Program

[0159] The "DOPE" program is a computer algorithm useful to optimize the nucleotide composition of a codon triplet in such a way that it encodes an amino acid distribution which resembles most the wanted amino acid distribution. In order to assess which of the possible distributions is the most similar to the wanted amino acid distribution, a scoring function is needed. In the "Dope" program the following function was found to be suited:

$$s \equiv \prod_{i=1}^N \left(\frac{x_i^{y_i}}{y_i^{y_i}} \frac{(1-x_i)^{1-y_i}}{(1-y_i)^{1-y_i}} \right)^{w_i},$$

where the x_i 's are the obtained amounts of amino acids and groups of amino acids as calculated by the program, y_i 's are the wanted amounts of amino acids and groups of amino acids as defined by the user of the program (e.g. specify which of the 20 amino acids or stop codons are wanted to be introduced, e.g. with a certain percentage (e.g. 90% Ala, 3% Ile, 7% Val), and w_i 's are assigned weight factors as defined by the user of the program (e.g., depending on the importance of having a specific amino acid residue inserted into the position in question). N is 21 plus the number of amino acid groups as defined by the user of the program. For purposes of this function 0° is defined as being 1.

[0160] A Monte-Carlo algorithm (one example being the one described by Valleau, J. P. & Whittington, S. G. (1977) A guide to Monte Carlo for statistical mechanics: 1 Highways. In "Statistical Mechanics, Part A" Equilibrium Techniques ed. B. J. Berne, New York: Plenum) is used for finding the maximum value of this function. In each iteration the following steps are performed:

[0161] 1. A new random nucleotide composition is chosen for each base, where the absolute difference between the current and the new composition is smaller than or equal to d for each of the four nucleotides G,A,T,C in all three positions of the codon (see below for definition of d).

[0162] 2. The scores of the new composition and the current composition are compared by the use of the function s as described above. If the new score is higher or equal to the score of the current composition, the new composition is kept and the current composition is changed to the new one. If the new score is smaller, the probability of keeping the new composition is $\exp(1000(\text{new_score} - \text{current_score}))$.

[0163] A cycle normally consists of 1000 iterations as described above in which d is decreasing linearly from 1 to 0. One hundred or more cycles are performed in an optimization process. The nucleotide composition resulting in the highest score is finally presented.

EXAMPLES

Example 1

Example on Homology Building of Termamyl™

[0164] The overall homology of the *B. licheniformis* α -amylase (in the following referred to as Termamyl™) to other Termamyl-like α -amylases is high and the percent similarity is extremely high. The similarity calculated for Termamyl™ to BSG (the *B. stearotheophilus* α -amylase having SEQ ID NO: 3), and BAN (the *B. amyloliquefaciens* α -amylase having SEQ ID NO: 5) using the University of Wisconsin Genetics Computer Group's program GCG gave 89% and 78%, respectively. TERM has a deletion of 2 residues between residue G180 and K181 compared to BAN™ and BSG. BSG has a deletion of 3 residues between G371 and 1372 in comparison with BAN™ and Termamyl™. Further BSG has a C-terminal extension of more than 20 residues compared to BAN™ and Termamyl™. BAN™ has 2 residues less and Termamyl has one residue less in the N-terminal compared to BSG.

[0165] The structure of the *B. licheniformis* (Termamyl™) and of the *B. amyloliquefaciens* α -amylase (BAN™), respectively, was model built on the structure disclosed in Appendix 1 of WO 96/23974. The structure of other Termamyl-like α -amylases (e.g. those disclosed herein) may be built analogously.

[0166] In comparison with the α -amylase used for elucidating the present structure, Termamyl™ differs in that it lacks two residues around 178-182. In order to compensate for this in the model structure, the HOMOLOG program from BIOSYM was used to substitute the residues in equivalent positions in the structure (not only structurally conserved regions) except for the deletion point. A peptide bond was established between G179(G177) and K180(K180) in Termamyl™ (BAN™). The close structural relationship between the solved structure and the model structure (and thus the validity of the latter) is indicated by the presence of only very few atoms found to be too close together in the model.

[0167] To this very rough structure of Termamyl™ was then added all waters (605) and ions (4 Calcium and 1 Sodium) from the solved structure (See Appendix 1 of WO 96/23874) at the same coordinates as for said solved structure using the INSIGHT program. This could be done with only few overlaps—in other words with a very nice fit. This model structure were then minimized using 200 steps of Steepest descent and 600 steps of Conjugated gradient (see Brooks et al 1983, J. Computational Chemistry 4, p. 187-217). The minimized structure was then subjected to molecular dynamics, 5 ps heating followed by up to 200 ps equilibration but more than 35 ps. The dynamics as run with the Verlet algorithm and the equilibration temperature 300K were kept using the Berendsen coupling to a water bath (Berendsen et. al., 1984, J. Chemical Physics 81, p. 3684-3690). Rotations and translations were removed every pico second.

Example 2

Method of Extracting Important Regions for Identifying α -Amylase Variants with Improved pH Stability and Altered Temperature Activity

[0168] The X-ray structure and/or the model build structure of the enzyme of interest, here SP722 and Termamyl™, are subjected to molecular dynamics simulations. The molecular dynamics simulation are made using the CHARMM (from Molecular simulations (MSI)) program or other suited program like, e.g., DISCOVER (from MSI). The molecular dynamic analysis is made in vacuum, or more preferred including crystal waters, or with the enzyme embedded in water, e.g., a water sphere or a water box. The simulation are run for 300 pico seconds (ps) or more, e.g., 300-1200 ps. The isotropic fluctuations are extracted for the CA carbons of the structures and compared between the structures. Where the sequence has deletions and/or insertions the isotropic fluctuations from the other structure are inserted thus giving 0 as difference in isotropic fluctuation. For explanation of isotropic fluctuations see the CHARMM manual (obtainable from MSI).

[0169] The molecular dynamics simulation can be done using standard charges on the chargeable amino acids. This is Asp and Glu are negatively charged and Lys and Arg are positively charged. This condition resembles the medium pH of approximately 7. To analyze a higher or lower pH, titration of the molecule can be done to obtain the altered pK_a 's of the standard titrateable residues normally within pH 2-10; Lys, Arg, Asp, Glu, Tyr and His. Also Ser, Thr and Cys are titrateable but are not taking into account here. Here the altered charges due to the pH has been described as both Asp and Glu are negative at high pH, and both Arg and Lys are uncharged.

This imitates a pH around 10 to 11 where the titration of Lys and Arg starts, as the normal pKa of these residues are around 9-11.

[0170] 1. The approach used for extracting important regions for identifying α -amylase variants with high pH stability:

[0171] The important regions for constructing variants with improved pH stability are the regions which at the extreme pH display the highest mobility, i.e., regions having the highest isotropic fluctuations.

[0172] Such regions are identified by carrying out two molecular dynamics simulations: i) a high pH run at which the basic amino acids, Lys and Arg, are seen as neutral (i.e. not protonated) and the acidic amino acids, Asp and Glu, have the charge (-1) and ii) a neutral pH run with the basic amino acids, Lys and Arg, having the net charge of (+1) and the acidic amino acids having a charge of (-1).

[0173] The two run are compared and regions displaying the relatively higher mobility at high pH compared to neutral pH analysis were identified.

[0174] Introduction of residues improving general stability, e.g., hydrogen bonding, making the region more rigid (by mutations such as Proline substitutions or replacement of Glycine residues), or improving the charges or their interaction, improves the high pH stability of the enzyme.

[0175] 2. The approach used for extracting regions for identifying α -amylase variants with increased activity at medium temperatures:

[0176] The important regions for constructing variants with increased activity at medium temperature was found as the difference between the isotropic fluctuations in SP722 and Termamyl, i.e., SP722 minus Termamyl CA isotropic fluctuations. The regions with the highest mobility in the isotropic fluctuations were selected. These regions and there residues were expected to increase the activity at medium temperatures. The activity of an alpha-amylase is only expressed if the correct mobility of certain residues are present. If the mobility of the residues is too low the activity is decreased or abandoned.

Example 3

Construction, by Localized Random, Doped Mutagenesis, of Termamyl-Like α -Amylase Variants Having an Improved Ca²⁺ Stability at Medium Temperatures Compared to the Parent Enzyme

[0177] To improve the stability at low calcium concentration of α -amylases random mutagenesis in pre-selected region was performed.

Region: Residue:

SAI: R181-W189

[0178] The DOPE software (see Materials and Methods) was used to determine spiked codons for each suggested change in the SA1 region minimizing the amount of stop codons (see table 1). The exact distribution of nucleotides was calculated in the three positions of the codon to give the suggested population of amino acid changes. The doped regions were doped specifically in the indicated positions to have a high chance of getting the desired residues, but still allow other possibilities.

TABLE 1

Distribution of amino acid residues for each position	
R181:	72% R, 2% N, 7% Q, 4% H, 4% K, 11% S
G182:	73% G, 13% A, 12% S, 2% T
K185:	95% K, 5% R
A186:	50% A, 4% N, 6% D, 1% E, 1% G, 1% K, 5% S, 31% T
W187:	100% W
D188:	100% D
W189:	92% W, 8% S

[0179] The resulting doped oligonucleotide strand is shown in table 2 as sense strand: with the wild type nucleotide and amino acid sequences and the distribution of nucleotides for each doped position.

TABLE 2

Position	181	182	185	186	187	188	189
Amino acid seq.	Arg	Gly	Lys	Ala	Thr	Asp	Thr
Wt nuc. seq.	cga	ggt	aaa	gct	tgg	gat	tgg

Forward primer (SEQ ID NO: 15):

FSA: 5'-caa aat cgt atc tac aaa ttc 123 456 a7g
8910 tgg gat t11g gaa gta gat tcg gaa aat-3'

Distribution of nucleotides for each doped

Position	
1:	35% A, 65% C
2:	83% G, 17% A
3:	63% G, 37% T
4:	86% G, 14% A
5:	85% G, 15% C
6:	50% T, 50% C
7:	95% A, 5% G
8:	58% G, 37% A, 5% T
9:	86% C, 13% A, 1% G
10:	83% T, 17% G
11:	92% G, 8% C

Reverse primer (SEQ ID NO: 16):

RSA: 5'-gaa ttt gta gat acg att ttg-3'

Random Mutagenesis

[0180] The spiked oligonucleotides apparent from Table 2 (which by a common term is designated FSA) and reverse primers RSA for the SA1 region and specific SEQ ID NO: 2: SP722 primers covering the SacII and the DraIII sites are used to generate PCR-library-fragments by the overlap extension method (Horton et al., Gene, 77 (1989), pp. 61-68) with an overlap of 21 base pairs. Plasmid pJE1 is template for the Polymerase Chain Reaction. The PCR fragments are cloned in the *E. coli*/Bacillus shuttle vector pDork101 (see Materials and Methods) enabling mutagenesis in *E. coli* and immediate expression in *Bacillus subtilis* preventing lethal accumulation of amylases in *E. coli*. After establishing the cloned PCR fragments in *E. coli*, a modified pUC19 fragment is digested out of the plasmid and the promoter and the mutated Termamyl gene is physically connected and expression can take place in *Bacillus*.

Screening

[0181] The library may be screened in the low calcium filter assays described in the "Material and Methods" section above.

Example 4

Construction of Variants of Amylase SEQ ID NO: 1
(SP690)

[0182] The gene encoding the amylase from SEQ ID NO: 1 is located in a plasmid pTVB106 described in WO96/23873. The amylase is expressed from the amyL promoter in this construct in *Bacillus subtilis*.

[0183] A variant of the protein is delta(T183-G184)+Y243F+Q391E+K444Q. Construction of this variant is described in WO96/23873.

[0184] Construction of delta(T183-G184)+N195F by the mega-primer method as described by Sarkar and Sommer, (1990), BioTechniques 8: 404-407.

[0185] Gene specific primer B1 (SEQ ID NO: 17) and mutagenic primer 101458 (SEQ ID NO: 19) were used to amplify by PCR an approximately 645 bp DNA fragment from a pTVB106-like plasmid (with the delta(T183-G184) mutations in the gene encoding the amylase from SEQ ID NO: 1).

[0186] The 645 bp fragment was purified from an agarose gel and used as a mega-primer together with primer Y2 (SEQ ID NO: 18) in a second PCR carried out on the same template.

[0187] The resulting approximately 1080 bp fragment was digested with restriction enzymes BstEII and AflIII and the resulting approximately 510 bp DNA fragment was purified and ligated with the pTVB106-like plasmid (with the delta(T183-G184) mutations in the gene encoding the amylase from SEQ ID NO: 1) digested with the same enzymes. Competent *Bacillus subtilis* SHA273 (amylase and protease low) cells were transformed with the ligation and Chloramphenicol resistant transformants and was checked by DNA sequencing to verify the presence of the correct mutations on the plasmid.

```

primer B1:
                    (SEQ ID NO: 17)
5' CGA TTG CTG ACG CTG TTA TTT GCG 3'

primer Y2:
                    (SEQ ID NO: 18)
5' CTT GTT CCC TTG TCA GAA CCA ATG 3'

primer 101458 (SEQ ID NO: 19):
5' GT CAT AGT TGC CGA AAT CTG TAT CGA CTT C 3'

```

[0188] The construction of variant: delta(T183-G184)+K185R+A186T was carried out in a similar way except that mutagenic primer 101638 was used.

```

primer 101638:
                    (SEQ ID NO: 20)
5' CC CAG TCC CAC GTA CGT CCC CTG AAT TTA TAT ATT
TTG 3'

```

[0189] Variants: delta(T183-G184)+A186T, delta(T183-G184)+A186I, delta(T183-G184)+A186S, delta(T183-G184)+A186N are constructed by a similar method except that pTVB106-like plasmid (carrying variant delta(T183-G184)+K185R+A186T) is used as template and as the vector for the cloning purpose. The mutagenic oligonucleotide (Oligo 1) is:

```

                    (SEQ ID NO: 21)
5' CC CAG TCC CAG NTCTTT CCC CTG AAT TTA TAT ATT
TTG 3'

```

[0190] N represents a mixture of the four bases: A, C, G, and T used in the synthesis of the mutagenic oligonucleotide. Sequencing of transformants identifies the correct codon for amino acid position 186 in the mature amylase.

[0191] Variant: delta(T183-G184)+K185R+A186T+N195F is constructed as follows:

PCR is carried out with primer x2 (SEQ ID NO: 22) and primer 101458 (SEQ ID NO: 19) on pTVB106-like plasmid (with mutations delta(T183-G184)+K185R+A186T). The resulting DNA fragment is used as a mega-primer together with primer Y2 (SEQ ID NO: 18) in a PCR on pTVB106-like plasmid (with mutations delta(T183-G184)+N195F). The product of the second PCR is digested with restriction endonucleases Acc65I and AflIII and cloned into pTVB106 like plasmid (delta(T183-G184)+N195F) digested with the same enzymes.

```

primer x2:
                    (SEQ ID NO: 22)
5' GCG TGG ACA AAG TTT GAT TTT CCT G 3'

```

[0192] Variant: delta(T183-G184)+K185R+A186T+N195F+Y243F+Q391E+K444Q is constructed as follows:

[0193] PCR is carried out with primer x2 and primer 101458 on pTVB106-like plasmid (with mutations delta(T183-G184)+K185R+A186T). The resulting DNA fragment is used as a mega-primer together with primer Y2 in a PCR on pTVB106 like plasmid (with mutations delta(T183-G184)+Y243F+Q391E+K444Q). The product of the second PCR is digested with restriction endonucleases Acc65I and AflIII and cloned into pTVB106 like plasmid (delta(T183-G184)+Y243F+Q391E+K444Q) digested with the same enzymes.

Example 5

Construction of Site-Directed α -Amylase Variants in
the Parent SP722 α -Amylase (SEQ ID NO: 2)

[0194] Construction of variants of amylase SEQ ID NO: 2 (SP722) is carried out as described below.

[0195] The gene encoding the amylase from SEQ ID NO: 2 is located in a plasmid pTVB112 described in WO 96/23873. The amylase is expressed from the amyL promoter in this construct in *Bacillus subtilis*.

[0196] Construction of delta(D183-G184)+V56I by the mega-primer method as described by Sarkar and Sommer, 1990 (BioTechniques 8: 404-407).

[0197] Gene specific primer DA03 and mutagenic primer DA07 are used to amplify by PCR an approximately 820 bp DNA fragment from a pTVB112-like plasmid (with the delta(D183-G184) mutations in the gene encoding the α -amylase shown in SEQ ID NO: 2).

[0198] The 820 bp fragment is purified from an agarose gel and used as a mega-primer together with primer DA01 in a second PCR carried out on the same template.

[0199] The resulting approximately 920 bp fragment is digested with restriction enzymes NgoM I and Aat II and the resulting approximately 170 bp DNA fragment is purified and ligated with the pTVB112-like plasmid (with the delta(D183-

G184) mutations in the gene encoding the amylase shown in SEQ ID NO: 2) digested with the same enzymes. Competent *Bacillus subtilis* SHA273 (amylase and protease low) cells are transformed with the ligation and Chloramphenicol resistant transformants are checked by DNA sequencing to verify the presence of the correct mutations on the plasmid.

primer DA01: (SEQ ID NO: 23)
5' CCTAATGATGGGAATCACTGG 3'

primer DA03: (SEQ ID NO: 24)
5' GCATTGGATGCTTTTGAACAACCG 3'

primer DA07 (SEQ ID NO: 25):
5' CGCAAAATGATATCGGTATGGAGCC 3'

Variants: delta(D183-G184)+K108L, delta(D183-G184)+K108Q, delta(D183-G184)+K108E, delta(D183-G184)+K108V, were constructed by the mega-primer method as described by Sarkar and Sommer, 1990 (BioTechniques 8: 404-407):

[0200] PCR is carried out with primer DA03 and mutagenesis primer DA20 on pTVB112-like plasmid (with mutations delta(D183-G184)). The resulting DNA fragment is used as a mega-primer together with primer DA01 in a PCR on pTVB112-like plasmid (with mutations delta(D183-G184)). The approximately 920 bp product of the second PCR is digested with restriction endonucleases Aat II and Mlu I and cloned into pTVB112-like plasmid (delta(D183-G184)) digested with the same enzymes.

primer DA20 (SEQ ID NO: 26):
5' GTGATGAACACSWAGGTGGAGCTGATGC 3'

[0201] S represents a mixture of the two bases: C and G used in the synthesis of the mutagenic oligonucleotide and W represents a mixture of the two bases: A and T used in the synthesis of the mutagenic oligonucleotide.

[0202] Sequencing of transformants identifies the correct codon for amino acid position 108 in the mature amylase.

[0203] Construction of the variants: delta(D183-G184)+D168A, delta(D183-G184)+D168I, delta(D183-G184)+D168V, delta(D183-G184)+D168T is carried out in a similar way except that mutagenic primer DA14 is used.

primer DA14 (SEQ ID NO: 27):
5' GATGGGTATGGRYCAATCAGACAATTCC 3'

[0204] R represents a mixture of the two bases: A and G used in the synthesis of the mutagenic oligonucleotide and Y represents a mixture of the two bases: C and T used in the synthesis of the mutagenic oligonucleotide.

[0205] Sequencing of transformants identifies the correct codon for amino acid position 168 in the mature amylase.

[0206] Construction of the variant: delta(D183-G184)+Q169N is carried out in a similar way except that mutagenic primer DA15 is used.

primer DA15 (SEQ ID NO: 28):
5' GGTGTATGGGATAACTCAGACAATTCC 3'

[0207] Construction of the variant: delta(D183-G184)+Q169L is carried out in a similar way except that mutagenic primer DA16 is used.

primer DA16 (SEQ ID NO: 29):
5' GGTGTATGGGATCTCTCAGACAATTCC 3'

[0208] Construction of the variant: delta(D183-G184)+Q172N is carried out in a similar way except that mutagenic primer DA17 is used.

primer DA17 (SEQ ID NO: 30):
5' GGGATCAATCACGAAATTTCCAAATCGTATC 3'

[0209] Construction of the variant: delta(D183-G184)+Q172L is carried out in a similar way except that mutagenic primer DA18 is used.

primer DA18 (SEQ ID NO: 31):
5' GGGATCAATCACGACTCTTCCAAATCGTATC 3'

[0210] Construction of the variant: delta(D183-G184)+L201I is carried out in a similar way except that mutagenic primer DA06 is used.

primer DA06 (SEQ ID NO: 32):
5' GGAAATTATGATTATATCATGTATGCAGATGTAG 3'

[0211] Construction of the variant: delta(D183-G184)+K269S is carried out in a similar way except that mutagenic primer DA09 is used.

primer DA09 (SEQ ID NO: 33):
5' GCTGAATTTTGGTCGAATGATTAGGTGCC 3'

[0212] Construction of the variant: delta(D183-G184)+K269Q is carried out in a similar way except that mutagenic primer DA11 is used.

primer DA11 (SEQ ID NO: 34):
5' GCTGAATTTTGGTCGAATGATTAGGTGCC 3'

[0213] Construction of the variant: delta(D183-G184)+N270Y is carried out in a similar way except that mutagenic primer DA21 is used.

primer DA21 (SEQ ID NO: 35):
5' GAATTTTGGAGTACGATTAGGTCCG 3'

[0214] Construction of the variants: delta(D183-G184)+L272A, delta(D183-G184)+L272I, delta(D183-G184)+L272V, delta(D183-G184)+L272T is carried out in a similar way except that mutagenic primer DA12 is used.

primer DA12 (SEQ ID NO: 36):
5' GGAAAAACGATRYCGGTGCCTTGAGAAC 3'

R represents a mixture of the two bases: A and G used in the synthesis of the mutagenic oligonucleotide and Y represents a mixture of the two bases: C and T used in the synthesis of the mutagenic oligonucleotide. Sequencing of transformants identifies the correct codon for amino acid position 272 in the mature amylase.

[0215] Construction of the variants: delta(D183-G184)+L275A, delta(D183-G184)+L275I, delta(D183-G184)+L275V, delta(D183-G184)+L275T is carried out in a similar way except that mutagenic primer DA13 is used.

primer DA13 (SEQ ID NO: 37):
5' GATTAGGTGCTRYCAGAACTATTTA 3'

R represents a mixture of the two bases: A and G used in the synthesis of the mutagenic oligonucleotide and Y represents a mixture of the two bases: C and T used in the synthesis of the mutagenic oligonucleotide.

Sequencing of transformants identifies the correct codon for amino acid position 275 in the mature amylase.

[0216] Construction of the variant: delta(D183-G184)+Y295E is carried out in a similar way except that mutagenic primer DA08 is used.

primer DA08 (SEQ ID NO: 38):
5' CCCCTTCATGAGAATCTTTATAACG 3'

[0217] Construction of delta(D183-G184)+K446Q by the mega-primer method as described by Sarkar and Sommer, 1990 (BioTechniques 8: 404-407):

[0218] Gene specific primer DA04, annealing 214-231 bp downstream relative to the STOP-codon and mutagenic primer DA10 were used to amplify by PCR an approximately 350 bp DNA fragment from a pTVB112-like plasmid (with the delta(D183-G184) mutations in the gene encoding the amylase depicted in SEQ ID NO: 2).

[0219] The resulting DNA fragment is used as a mega-primer together with primer DA05 in a PCR on pTVB112 like plasmid (with mutations delta(D183-G184)). The app. 460 bp product of the second PCR is digested with restriction endonucleases SnaB I and Not I and cloned into pTVB112 like plasmid (delta(D183-G184)) digested with the same enzymes.

primer DA04 (SEQ ID NO: 39):
5' GAATCCGAACCTATTACACATTGC 3'

primer DA05 (SEQ ID NO: 40):
5' CGGATGGACTCGAGAAGGAATACCACG 3'

primer DA10 (SEQ ID NO: 41):
5' CGTAGGGCAAAATCAGGCCGGTCAAGTTTGG 3'

[0220] Construction of the variants: delta(D183-G184)+K458R is carried out in a similar way except that mutagenic primer DA22 is used.

primer DA22 (SEQ ID NO: 42):
5' CATAACTGGAAATCGCCCGGAACAGTTACG 3'

[0221] Construction of the variants: delta(D183-G184)+P459S and delta(D183-G184)+P459T is carried out in a similar way except that mutagenic primer DA19 is used.

primer DA19 (SEQ ID NO: 43):
5' CTGGAATAAAWCCGGAACAGTTACG 3'

W represents a mixture of the two bases: A and T used in the synthesis of the mutagenic oligonucleotide.

Sequencing of transformants identifies the correct codon for amino acid position 459 in the mature amylase.

[0222] Construction of the variants: delta(D183-G184)+T461P is carried out in a similar way except that mutagenic primer DA23 is used.

primer DA23 (SEQ ID NO: 44):
5' GGAAATAAACCCAGGACCCGTTACGATCAATGC 3'

[0223] Construction of the variant: delta(D183-G184)+K142R is carried out in a similar way except that mutagenic primer DA32 is used.

Primer DA32 (SEQ ID NO: 45):
5' GAGGCTTGGACTAGGTTTGTATTTCCAG 3'

[0224] Construction of the variant: delta(D183-G184)+K269R is carried out in a similar way except that mutagenic primer DA31 is used.

Primer DA31 (SEQ ID NO: 46):
5' GCTGAATTTTGGCGCAATGATTTAGGTGCC 3'

Example 6

Construction of Site-Directed α -Amylase Variants in the Parent Termamyl α -Amylase (SEQ ID NO: 4)

[0225] The amyL gene, encoding the Termamyl α -amylase is located in plasmid pDN1528 described in WO 95/10603 (Novo Nordisk). Variants with substitutions N265R and N265D, respectively, of said parent α -amylase are constructed by methods described in WO 97/41213 or by the "megaprimer" approach described above.

Mutagenic Oligonucleotides are:

[0226]

Primer b11 for the N265R substitution:
(SEQ ID NO: 56)

5' PCC AGC GCG CCT AGG TCA CGC TGC CAA TAT TCA G

Primer b12 for the N265D substitution:
(SEQ ID NO: 57)

5' PCC AGC GCG CCT AGG TCA TCC TGC CAA TAT TCA G

P represents a phosphate group.

Example 7

Determination of pH Stability at Alkaline pH of Variants of the Parent α -Amylase Having the Amino Acid Sequence Shown in SEQ ID NO:2

[0227] In this series of analysis purified enzyme samples were used. The measurements were made using solutions of the respective variants in 100 mM CAPS buffer adjusted to pH 10.5. The solutions were incubated at 75° C.

[0228] After incubation for 20 and 30 min the residual activity was measured using the PNP-G7 assay (described in the "Materials and Methods" section above). The residual activity in the samples was measured using Britton Robinson buffer pH 7.3. The decline in residual activity was measured

relative to a corresponding reference solution of the same enzyme at 0 minutes, which has not been incubated at high pH and 75° C.

[0229] The percentage of the initial activity as a function is shown in the table below for the parent enzyme (SEQ ID NO: 2) and for the variants in question.

Variant	Residual activity after 20 min	Residual activity after 30 min
Δ(D183-G184) + M323L	56%	44%
Δ(D183-G184) + M323L + R181S	67%	55%
Δ(D183-G184) + M323L + A186T	62%	50%

[0230] In an other series of analysis culture supernatants were used. The measurements were made using solutions of the respective variants in 100 mM CAPS buffer adjusted to pH 10.5. The solutions were incubated at 80° C.

[0231] After incubation for 30 minutes the residual activity was measured using the Phadebas assay (described in the “Materials and Method” section above. The residual activity in the samples was measured using Britton Robinson buffer pH 7.3. The decline in residual activity was measured relative to a corresponding reference solution of the same enzyme at 0 minutes, which has not been incubated at high pH and 80° C.

[0232] The percentage of the initial activity as a function is shown in the table below for the parent enzyme (SEQ ID NO: 2) and for the variants in question.

Variant	Residual activity after 30 min
Δ(D183-G184)	4%
Δ(D183-G184) + P459T	25%
Δ(D183-G184) + K458R	31%
Δ(D183-G184) + K311R	10%

Example 8

Determination of Calcium Stability at Alkaline pH of Variants of the Parent α-Amylase Having the Amino Acid Sequence Shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 4

A: Calcium Stability of Variants of the Sequence in SEQ ID NO: 1

[0233] The measurement were made using solutions of the respective variants in 100 mM CAPS buffer adjusted to pH 10.5 to which polyphosphate was added (at time t=0) to give a final concentration of 2400 ppm. The solutions were incubated at 50° C.

[0234] After incubation for 20 and 30 minutes the residual activity was measured using the PNP-G7 assay (described above). The residual activity in the samples was measured using Britton Robinson buffer pH 7.3. The decline in residual activity was measured relative to a corresponding reference solution of the same enzyme at 0 minutes, which has not been incubated at high pH and 50° C.

[0235] The percentage of the initial activity as a function is shown in the table below for the parent enzyme (SEQ ID NO: 1) and for the variants in question.

Variant	Residual activity after 20 min	Residual activity after 30 min
Δ(T183-G184)	32%	19%
Δ(T183-G184) + A186T	36%	23%
Δ(T183-G184) + K185R + A186T	45%	29%
Δ(T183-G184) + A186I	35%	20%
Δ(T183-G184) + N195F	44%	n.d.

n.d. = Not determined

B: Calcium Stability of Variants of the Sequence in SEQ ID NO: 2

[0236] In this serie of analysis purified samples of enzymes were used. The measurement were made using solutions of the respective variants in 100 mM CAPS buffer adjusted to pH 10.5 to which polyphosphate was added (at time t=0) to give a final concentration of 2400 ppm. The solutions were incubated at 50° C.

[0237] After incubation for 20 and 30 minutes the residual activity was measured using the PNP-G7 assay (described above). The residual activity in the samples was measured using Britton Robinson buffer pH 7.3. The decline in residual activity was measured relative to a corresponding reference solution of the same enzyme at 0 minutes, which has not been incubated at high pH and 50° C.

[0238] The percentage of the initial activity as a function is shown in the table below for the parent enzyme (SEQ ID NO: 2) and for the variants in question.

Variant	Residual activity after 20 min	Residual activity after 30 min
Δ(D183-G184) + M323L	21%	13%
Δ(D183-G184) + M323L + R181S	32%	19%
Δ(D183-G184) + M323L + A186T	28%	17%
Δ(D183-G184) + M323L + A186R	30%	18%
Δ(D183-G184)	30%	20%
Δ(D183-G184) + N195F	55%	44%

[0239] In this serie of analysis culture supernatants were used. The measurement were made using solutions of the respective variants in 100 mM CAPS buffer adjusted to pH 10.5 to which polyphosphate was added (at time t=0) to give a final concentration of 2400 ppm. The solutions were incubated at 50° C.

[0240] After incubation for 30 minutes the residual activity was measured using the Phadebas assay as described above. The residual activity in the samples was measured using Britton Robinson buffer pH 7.3. The decline in residual activity was measured relative to a corresponding reference solution of the same enzyme at 0 minutes, which has not been incubated at high pH and 50° C.

[0241] The percentage of the initial activity as a function is shown in the table below for the parent enzyme (SEQ ID NO: 2) and for the variants in question.

Variant	Residual activity after 30 min
Δ(D183-G184)	0%
Δ(D183-G184) + P459T	19%
Δ(D183-G184) + K458R	18%

-continued

Variant	Residual activity after 30 min
Δ (D183-G184) + T461P	13%
Δ (D183-G184) + E346Q + K385R	4%

C: Calcium Stability of Variants of the Sequence in SEQ ID NO: 4 The measurement were made using solutions of the respective variants in 100 mM CAPS buffer adjusted to pH 10.5 to which polyphosphate was added (at time t=0) to give a final concentration of 2400 ppm. The solutions were incubated at 60° C. for 20 minutes.

[0242] After incubation for 20 minutes the residual activity was measured using the PNP-G7 assay (described above). The residual activity in the samples was measured using Britton Robinson buffer pH 7.3. The decline in residual activity was measured relative to a corresponding reference solution of the same enzyme at 0 minutes, which has not been incubated at high pH and 60° C.

[0243] The percentage of the initial activity as a function is shown in the table below for the parent enzyme (SEQ ID NO: 4) and for the variants in question.

Variant	Residual activity after 20 min
Termamyl (SEQ ID NO: 4)	17%
N265R	28%
N265D	25%

Example 9

Activity Measurement at Medium Temperature of α -Amylases Having the Amino Acid Sequence Shown in SEQ ID NO: 1

A: α -Amylase Activity of Variants of the Sequence in SEQ ID NO:1

[0244] The measurement were made using solutions of the respective variants in 50 mM Britton Robinson buffer adjusted to pH 7.3 and using the Phadebas assay described above. The activity in the samples was measured at 37° C. using 50 mM Britton Robinson buffer pH 7.3 and at 25° C. using 50 mM CAPS buffer pH 10.5.

[0245] The temperature dependent activity and the percentage of the activity at 25° C. relative to the activity at 37° C. is shown in the table below for the parent enzyme (SEQ ID NO: 1) and for the variants in question.

Variant	NU/mg 25° C.	NU/mg 37° C.	NU(25° C.)/ NU(37° C.)
SP690	1440	35000	4.1%
Δ (T183-G184)	2900	40000	7.3%
Δ (T183-G184) + K269S	1860	12000	15.5%
Δ (Q174)	3830	38000	7.9%

[0246] Another measurement was made using solutions of the respective variants in 50 mM Britton Robinson buffer adjusted to pH 7.3 and using the Phadebas assay described

above. The activity in the samples was measured at 37° C. and 50° C. using 50 mM Britton Robinson buffer pH 7.3.

[0247] The temperature dependent activity and the percentage of the activity at 37° C. relative to the activity at 50° C. is shown in the table below for the parent enzyme (SEQ ID NO: 1) and for the variants in question.

Variant	NU/mg 37° C.	NU/mg 50° C.	NU(37° C.)/ NU(50° C.)
SP690 (seq ID NO: 1)	13090	21669	60%
K269Q	7804	10063	78%

B: α -Amylase Activity of Variants of the Sequence in SEQ ID NO:2

[0248] The measurement were made using solutions of the respective variants in 50 mM Britton Robinson buffer adjusted to pH 7.3 and using the Phadebas assay described above. The activity in the samples was measured at both 25° C. and 37° C. using 50 mM Britton Robinson buffer pH 7.3.

[0249] The temperature dependent activity and the percentage of the activity at 25° C. relative to the activity at 37° C. is shown in the table below for the parent enzyme (SEQ ID NO: 2) and for the variants in question.

Variant	NU/mg 25° C.	NU/mg 37° C.	NU(25° C.)/ NU(37° C.)
Δ (D183-G184) + M323L	3049	10202	30%
Δ (D183-G184) + M323L + R181S	18695	36436	51%

C: α -Amylase Activity of Variants of the Sequence in SEQ ID NO:4

[0250] The measurement were made using solutions of the respective variants in 50 mM Britton Robinson buffer adjusted to pH 7.3 and using the Phadebas assay described above. The activity in the samples was measured at both 37° C. using 50 mM Britton Robinson buffer pH 7.3 and at 60° C. using 50 mM CAPS buffer pH 10.5.

[0251] The temperature dependent activity and the percentage of the activity at 37° C. relative to the activity at 60° C. is shown in the table below for the parent enzyme (SEQ ID NO: 4) and for the variants in question.

Variant	NU/mg 37° C.	NU/mg 60° C.	NU(37° C.)/NU(60° C.)
Termamyl	7400	4350	170%
Q264S	10000	4650	215%

Example 10

Construction of Variants of Parent Hybrid BAN:1-300/Termamyl:301-483 α -Amylase

[0252] Plasmid pTVB191 contains the gene encoding hybrid α -amylase BAN:1-300/Termamyl:301-483 as well as an origin of replication functional in *Bacillus subtilis* and the cat gene conferring chloramphenicol resistance.

[0253] Variant BM4 (F290E) was constructed using the megaprimer approach (Sarkar and Sommer, 1990) with plasmid pTVB191 as template.

[0254] Primer p1 (SEQ ID NO: 52) and mutagenic oligonucleotide bm4 (SEQ ID NO: 47) were used to amplify a 444 bp fragment with polymerase chain reaction (PCR) under standard conditions.

This fragment was purified from an agarose gel and used as 'Megaprimer' in a second PCR with primer p2 (SEQ ID NO: 53) resulting in a 531 bp fragment. This fragment was digested with restriction endonucleases *Hin*DIII and *Tth*111I. The 389 bp fragment produced by this was ligated into plasmid pTVB191 that had been cleaved with the same two enzymes. The resulting plasmid was transformed into *B. subtilis* SHA273. Chloramphenicol resistant clones were selected by growing the transformants on plates containing chloramphenicol as well as insoluble starch. Clones expressing an active α -amylase were isolated by selecting clones that formed halos after staining the plates with iodine vapour. The identity of the introduced mutations was confirmed by DNA sequencing.

[0255] Variants BM5(F290K), BM6(F290A), BM8 (Q360E) and BM11(N102D) were constructed in a similar way. Details of their construction are given below.

Variant: BM5(F290K)

[0256] mutagenic oligonucleotide: bm5 (SEQ ID NO: 48)

Primer (1st PCR): p1 (SEQ ID NO: 52)

[0257] Size of resulting fragment: 444 bp

Primer (2nd PCR): p2 (SEQ ID NO: 53)

[0258] Restriction endonucleases: *Hin*DIII, *Tth*111I
Size of cleaved fragment: 389 bp

Variant: BM6(F290A)

[0259] mutagenic oligonucleotide: bm6 (SEQ ID NO: 49)

Primer (1st PCR): p1 (SEQ ID NO: 52)

[0260] Size of resulting fragment: 444 bp

Primer (2nd PCR): p2 (SEQ ID NO: 53)

[0261] Restriction endonucleases: *Hin*DIII, *Tth*111I
Size of cleaved fragment: 389 bp

Variant: BM8(Q360E)

[0262] mutagenic oligonucleotide: bm8 (SEQ ID NO: 50)

Primer (1st PCR): p1 (SEQ ID NO: 52)

[0263] Size of resulting fragment: 230 bp

Primer (2nd PCR): p2 (SEQ ID NO: 53)

[0264] Restriction endonucleases: *Hin*DIII, *Tth*111I
Size of cleaved fragment: 389 bp

Variant: BM11(N102D)

[0265] mutagenic oligonucleotide: bm11 (SEQ ID NO: 51)

Primer (1st PCR): p3 (SEQ ID NO: 54)

[0266] Size of resulting fragment: 577

Primer (2nd PCR): p4 (SEQ ID NO: 55)

[0267] Restriction endonucleases: *Hin*DIII, *Pvu*I
Size of cleaved fragment: 576

Mutagenic Oligonucleotides:

[0268]

bm4 (SEQ ID NO: 47): F290E
primer 5' GTG TTT GAC GTC CCG CTT CAT GAG AAT
TTA CAG G

bm5 (SEQ ID NO: 48): F290K
primer 5' GTG TTT GAC GTC CCG CTT CAT AAG AAT
TTA CAG G

bm6 (SEQ ID NO: 49): F290A
primer 5' GTG TTT GAC GTC CCG CTT CAT GCC AAT
TTA CAG G

bm8 (SEQ ID NO: 50): Q360E
primer 5' AGG GAA TCC GGA TAC CCT GAG GTT TTC
TAC GG

bm11 (SEQ ID NO: 51): N102D
primer 5' GAT GTG GTT TTG GAT CAT AAG GCC GGC
GCT GAT G

Other Primers:

[0269]

p1: 5' CTG TTA TTA ATG CCG CCA AAC C (SEQ ID NO: 52)
p2: 5' G GAA AAG AAA TGT TTA CGG TTG CG (SEQ ID NO: 53)
p3: 5' G AAA TGA AGC GGA ACA TCA AAC ACG (SEQ ID NO: 54)
p4: 5' GTA TGA TTT AGG AGA ATT CC (SEQ ID NO: 55)

Example 11

α -Amylase Activity at Alkaline pH of Variants of Parent BAN:1-300/Termamyl:301-483 Hybrid α -Amylase

[0270] The measurements were made using solutions for the respective enzymes and utilizing the Phadebas assay (described above). The activity was measured after incubating for 15 minutes at 30° C. in 50 mM Britton-Robinson buffer adjusted to the indicated pH by NaOH.

NU/mg enzyme						
pH	wt	Q360E	F290A	F290K	F290E	N102D
8.0	5300	7800	8300	4200	6600	6200
9.0	1600	2700	3400	2100	1900	1900

REFERENCES CITED

- [0271] Klein, C., et al., *Biochemistry* 1992, 31, 8740-8746,
[0272] Mizuno, H., et al., *J. Mol. Biol.* (1993) 234, 1282-1283,

- [0273] Chang, C., et al., *J. Mol. Biol.* (1993) 229, 235-238,
 [0274] Larson, S. B., *J. Mol. Biol.* (1994) 235, 1560-1584,
 [0275] Lawson, C. L., *J. Mol. Biol.* (1994) 236, 590-600,
 [0276] Qian, M., et al., *J. Mol. Biol.* (1993) 231, 785-799,
 [0277] Brady, R. L., et al., *Acta Crystallogr. sect. B*, 47, 527-535,
 [0278] Swift, H. J., et al., *Acta Crystallogr. sect. B*, 47, 535-544
 [0279] A. Kadziola, Ph.D. Thesis: "An alpha-amylase from Barley and its Complex with a Substrate Analogue Inhibitor Studied by X-ray Crystallography", Department of Chemistry University of Copenhagen 1993
 [0280] MacGregor, E. A., *Food Hydrocolloids*, 1987, Vol. 1, No. 5-6, p.
 [0281] B. Diderichsen and L. Christiansen, Cloning of a maltogenic α -amylase from *Bacillus stearotheophilus*, *FEMS Microbiol. letters*: 56: pp. 53-60 (1988)
 [0282] Hudson et al., *Practical Immunology*, Third edition (1989), Blackwell Scientific Publications,
 [0283] Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor, 1989
 [0284] S. L. Beaucage and M. H. Caruthers, *Tetrahedron Letters* 22, 1981, pp. 1859-1869
 [0285] Matthes et al., *The EMBO J.* 3, 1984, pp. 801-805.
 [0286] R. K. Saiki et al., *Science* 239, 1988, pp. 487-491.
 [0287] Morinaga et al., (1984, *Biotechnology* 2:646-639)
 [0288] Nelson and Long, *Analytical Biochemistry* 180, 1989, pp. 147-151
 [0289] Hunkapiller et al., 1984, *Nature* 310:105-111
 [0290] R. Higuchi, B. Krummel, and R. K. Saiki (1988). A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. *Nucl. Acids Res.* 16:7351-7367.
 [0291] Dubnau et al., 1971, *J. Mol. Biol.* 56, pp. 209-221.
 [0292] Gryczan et al., 1978, *J. Bacteriol.* 134, pp. 318-329.
 [0293] S. D. Erlich, 1977, *Proc. Natl. Acad. Sci.* 74, pp. 1680-1682.
 [0294] Boel et al., 1990, *Biochemistry* 29, pp. 6244-6249.

 SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 58

<210> SEQ ID NO 1

<211> LENGTH: 485

<212> TYPE: PRT

<213> ORGANISM: *Bacillus* sp.

<400> SEQUENCE: 1

```

His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr
1          5          10          15

Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ala
          20          25          30

Asn Leu Lys Ser Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp
          35          40          45

Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr
          50          55          60

Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly
          65          70          75          80

Thr Arg Asn Gln Leu Gln Ala Ala Val Thr Ser Leu Lys Asn Asn Gly
          85          90          95

Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp
          100          105          110

Gly Thr Glu Ile Val Asn Ala Val Glu Val Asn Arg Ser Asn Arg Asn
          115          120          125

Gln Glu Thr Ser Gly Glu Tyr Ala Ile Glu Ala Trp Thr Lys Phe Asp
          130          135          140

Phe Pro Gly Arg Gly Asn Asn His Ser Ser Phe Lys Trp Arg Trp Tyr
          145          150          155          160

His Phe Asp Gly Thr Asp Trp Asp Gln Ser Arg Gln Leu Gln Asn Lys
          165          170          175

Ile Tyr Lys Phe Arg Gly Thr Gly Lys Ala Trp Asp Trp Glu Val Asp
          180          185          190

Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Met
          195          200          205

Asp His Pro Glu Val Ile His Glu Leu Arg Asn Trp Gly Val Trp Tyr
          210          215          220

```

-continued

Thr Asn Thr Leu Asn Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His
 225 230 235 240
 Ile Lys Tyr Ser Phe Thr Arg Asp Trp Leu Thr His Val Arg Asn Thr
 245 250 255
 Thr Gly Lys Pro Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu
 260 265 270
 Gly Ala Ile Glu Asn Tyr Leu Asn Lys Thr Ser Trp Asn His Ser Val
 275 280 285
 Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Asn Ser Gly
 290 295 300
 Gly Tyr Tyr Asp Met Arg Asn Ile Leu Asn Gly Ser Val Val Gln Lys
 305 310 315 320
 His Pro Thr His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro
 325 330 335
 Gly Glu Ala Leu Glu Ser Phe Val Gln Gln Trp Phe Lys Pro Leu Ala
 340 345 350
 Tyr Ala Leu Val Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr
 355 360 365
 Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala Met Lys Ser
 370 375 380
 Lys Ile Asp Pro Leu Leu Gln Ala Arg Gln Thr Phe Ala Tyr Gly Thr
 385 390 395 400
 Gln His Asp Tyr Phe Asp His His Asp Ile Ile Gly Trp Thr Arg Glu
 405 410 415
 Gly Asn Ser Ser His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp
 420 425 430
 Gly Pro Gly Gly Asn Lys Trp Met Tyr Val Gly Lys Asn Lys Ala Gly
 435 440 445
 Gln Val Trp Arg Asp Ile Thr Gly Asn Arg Thr Gly Thr Val Thr Ile
 450 455 460
 Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser
 465 470 475 480
 Val Trp Val Lys Gln
 485

<210> SEQ ID NO 2

<211> LENGTH: 485

<212> TYPE: PRT

<213> ORGANISM: Bacillus sp.

<400> SEQUENCE: 2

His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp His
 1 5 10 15
 Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ser
 20 25 30
 Asn Leu Arg Asn Arg Gly Ile Thr Ala Ile Trp Ile Pro Pro Ala Trp
 35 40 45
 Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr
 50 55 60
 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly
 65 70 75 80
 Thr Arg Ser Gln Leu Glu Ser Ala Ile His Ala Leu Lys Asn Asn Gly

85																90								95					
Val	Gln	Val	Tyr	Gly	Asp	Val	Val	Met	Asn	His	Lys	Gly	Gly	Ala	Asp														
100																105								110					
Ala	Thr	Glu	Asn	Val	Leu	Ala	Val	Glu	Val	Asn	Pro	Asn	Asn	Arg	Asn														
115																120								125					
Gln	Glu	Ile	Ser	Gly	Asp	Tyr	Thr	Ile	Glu	Ala	Trp	Thr	Lys	Phe	Asp														
130																135								140					
Phe	Pro	Gly	Arg	Gly	Asn	Thr	Tyr	Ser	Asp	Phe	Lys	Trp	Arg	Trp	Tyr														
145																150								160					
His	Phe	Asp	Gly	Val	Asp	Trp	Asp	Gln	Ser	Arg	Gln	Phe	Gln	Asn	Arg														
165																170								175					
Ile	Tyr	Lys	Phe	Arg	Gly	Asp	Gly	Lys	Ala	Trp	Asp	Trp	Glu	Val	Asp														
180																185								190					
Ser	Glu	Asn	Gly	Asn	Tyr	Asp	Tyr	Leu	Met	Tyr	Ala	Asp	Val	Asp	Met														
195																200								205					
Asp	His	Pro	Glu	Val	Val	Asn	Glu	Leu	Arg	Arg	Trp	Gly	Glu	Trp	Tyr														
210																215								220					
Thr	Asn	Thr	Leu	Asn	Leu	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Val	Lys	His														
225																230								235					
Ile	Lys	Tyr	Ser	Phe	Thr	Arg	Asp	Trp	Leu	Thr	His	Val	Arg	Asn	Ala														
245																250								255					
Thr	Gly	Lys	Glu	Met	Phe	Ala	Val	Ala	Glu	Phe	Trp	Lys	Asn	Asp	Leu														
260																265								270					
Gly	Ala	Leu	Glu	Asn	Tyr	Leu	Asn	Lys	Thr	Asn	Trp	Asn	His	Ser	Val														
275																280								285					
Phe	Asp	Val	Pro	Leu	His	Tyr	Asn	Leu	Tyr	Asn	Ala	Ser	Asn	Ser	Gly														
290																295								300					
Gly	Asn	Tyr	Asp	Met	Ala	Lys	Leu	Leu	Asn	Gly	Thr	Val	Val	Gln	Lys														
305																310								315					
His	Pro	Met	His	Ala	Val	Thr	Phe	Val	Asp	Asn	His	Asp	Ser	Gln	Pro														
325																330								335					
Gly	Glu	Ser	Leu	Glu	Ser	Phe	Val	Gln	Glu	Trp	Phe	Lys	Pro	Leu	Ala														
340																345								350					
Tyr	Ala	Leu	Ile	Leu	Thr	Arg	Glu	Gln	Gly	Tyr	Pro	Ser	Val	Phe	Tyr														
355																360								365					
Gly	Asp	Tyr	Tyr	Gly	Ile	Pro	Thr	His	Ser	Val	Pro	Ala	Met	Lys	Ala														
370																375								380					
Lys	Ile	Asp	Pro	Ile	Leu	Glu	Ala	Arg	Gln	Asn	Phe	Ala	Tyr	Gly	Thr														
385																390								395					
Gln	His	Asp	Tyr	Phe	Asp	His	His	Asn	Ile	Ile	Gly	Trp	Thr	Arg	Glu														
405																410								415					
Gly	Asn	Thr	Thr	His	Pro	Asn	Ser	Gly	Leu	Ala	Thr	Ile	Met	Ser	Asp														
420																425								430					
Gly	Pro	Gly	Gly	Glu	Lys	Trp	Met	Tyr	Val	Gly	Gln	Asn	Lys	Ala	Gly														
435																440								445					
Gln	Val	Trp	His	Asp	Ile	Thr	Gly	Asn	Lys	Pro	Gly	Thr	Val	Thr	Ile														
450																455								460					
Asn	Ala	Asp	Gly	Trp	Ala	Asn	Phe	Ser	Val	Asn	Gly	Gly	Ser	Val	Ser														
465																470								475					
Ile	Trp	Val	Lys	Arg																									
485																													

-continued

```

<210> SEQ ID NO 3
<211> LENGTH: 514
<212> TYPE: PRT
<213> ORGANISM: Bacillus stearothermophilus

<400> SEQUENCE: 3
Ala Ala Pro Phe Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr Leu
1          5          10          15
Pro Asp Asp Gly Thr Leu Trp Thr Lys Val Ala Asn Glu Ala Asn Asn
20        25        30
Leu Ser Ser Leu Gly Ile Thr Ala Leu Trp Leu Pro Pro Ala Tyr Lys
35        40        45
Gly Thr Ser Arg Ser Asp Val Gly Tyr Gly Val Tyr Asp Leu Tyr Asp
50        55        60
Leu Gly Glu Phe Asn Gln Lys Gly Ala Val Arg Thr Lys Tyr Gly Thr
65        70        75        80
Lys Ala Gln Tyr Leu Gln Ala Ile Gln Ala Ala His Ala Ala Gly Met
85        90        95
Gln Val Tyr Ala Asp Val Val Phe Asp His Lys Gly Gly Ala Asp Gly
100       105       110
Thr Glu Trp Val Asp Ala Val Glu Val Asn Pro Ser Asp Arg Asn Gln
115       120       125
Glu Ile Ser Gly Thr Tyr Gln Ile Gln Ala Trp Thr Lys Phe Asp Phe
130       135       140
Pro Gly Arg Gly Asn Thr Tyr Ser Ser Phe Lys Trp Arg Trp Tyr His
145       150       155       160
Phe Asp Gly Val Asp Trp Asp Glu Ser Arg Lys Leu Ser Arg Ile Tyr
165       170       175
Lys Phe Arg Gly Ile Gly Lys Ala Trp Asp Trp Glu Val Asp Thr Glu
180       185       190
Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Leu Asp Met Asp His
195       200       205
Pro Glu Val Val Thr Glu Leu Lys Ser Trp Gly Lys Trp Tyr Val Asn
210       215       220
Thr Thr Asn Ile Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys
225       230       235       240
Phe Ser Phe Phe Pro Asp Trp Leu Ser Asp Val Arg Ser Gln Thr Gly
245       250       255
Lys Pro Leu Phe Thr Val Gly Glu Tyr Trp Ser Tyr Asp Ile Asn Lys
260       265       270
Leu His Asn Tyr Ile Met Lys Thr Asn Gly Thr Met Ser Leu Phe Asp
275       280       285
Ala Pro Leu His Asn Lys Phe Tyr Thr Ala Ser Lys Ser Gly Gly Thr
290       295       300
Phe Asp Met Arg Thr Leu Met Thr Asn Thr Leu Met Lys Asp Gln Pro
305       310       315       320
Thr Leu Ala Val Thr Phe Val Asp Asn His Asp Thr Glu Pro Gly Gln
325       330       335
Ala Leu Gln Ser Trp Val Asp Pro Trp Phe Lys Pro Leu Ala Tyr Ala
340       345       350
Phe Ile Leu Thr Arg Gln Glu Gly Tyr Pro Cys Val Phe Tyr Gly Asp

```

-continued

355					360					365					
Tyr	Tyr	Gly	Ile	Pro	Gln	Tyr	Asn	Ile	Pro	Ser	Leu	Lys	Ser	Lys	Ile
370					375					380					
Asp	Pro	Leu	Leu	Ile	Ala	Arg	Arg	Asp	Tyr	Ala	Tyr	Gly	Thr	Gln	His
385					390					395					400
Asp	Tyr	Leu	Asp	His	Ser	Asp	Ile	Ile	Gly	Trp	Thr	Arg	Glu	Gly	Val
			405						410					415	
Thr	Glu	Lys	Pro	Gly	Ser	Gly	Leu	Ala	Ala	Leu	Ile	Thr	Asp	Gly	Pro
			420					425					430		
Gly	Gly	Ser	Lys	Trp	Met	Tyr	Val	Gly	Lys	Gln	His	Ala	Gly	Lys	Val
		435					440					445			
Phe	Tyr	Asp	Leu	Thr	Gly	Asn	Arg	Ser	Asp	Thr	Val	Thr	Ile	Asn	Ser
450					455					460					
Asp	Gly	Trp	Gly	Glu	Phe	Lys	Val	Asn	Gly	Gly	Ser	Val	Ser	Val	Trp
465					470					475					480
Val	Pro	Arg	Lys	Thr	Thr	Val	Ser	Thr	Ile	Ala	Trp	Ser	Ile	Thr	Thr
			485						490					495	
Arg	Pro	Trp	Thr	Asp	Glu	Phe	Val	Arg	Trp	Thr	Glu	Pro	Arg	Leu	Val
			500					505					510		
Ala Trp															
<210> SEQ ID NO 4															
<211> LENGTH: 483															
<212> TYPE: PRT															
<213> ORGANISM: Bacillus licheniformis															
<400> SEQUENCE: 4															
Ala	Asn	Leu	Asn	Gly	Thr	Leu	Met	Gln	Tyr	Phe	Glu	Trp	Tyr	Met	Pro
1			5						10					15	
Asn	Asp	Gly	Gln	His	Trp	Arg	Arg	Leu	Gln	Asn	Asp	Ser	Ala	Tyr	Leu
			20				25						30		
Ala	Glu	His	Gly	Ile	Thr	Ala	Val	Trp	Ile	Pro	Pro	Ala	Tyr	Lys	Gly
		35					40					45			
Thr	Ser	Gln	Ala	Asp	Val	Gly	Tyr	Gly	Ala	Tyr	Asp	Leu	Tyr	Asp	Leu
		50					55					60			
Gly	Glu	Phe	His	Gln	Lys	Gly	Thr	Val	Arg	Thr	Lys	Tyr	Gly	Thr	Lys
65				70					75					80	
Gly	Glu	Leu	Gln	Ser	Ala	Ile	Lys	Ser	Leu	His	Ser	Arg	Asp	Ile	Asn
			85						90					95	
Val	Tyr	Gly	Asp	Val	Val	Ile	Asn	His	Lys	Gly	Gly	Ala	Asp	Ala	Thr
		100					105						110		
Glu	Asp	Val	Thr	Ala	Val	Glu	Val	Asp	Pro	Ala	Asp	Arg	Asn	Arg	Val
		115					120					125			
Ile	Ser	Gly	Glu	His	Leu	Ile	Lys	Ala	Trp	Thr	His	Phe	His	Phe	Pro
		130					135					140			
Gly	Arg	Gly	Ser	Thr	Tyr	Ser	Asp	Phe	Lys	Trp	His	Trp	Tyr	His	Phe
145				150					155					160	
Asp	Gly	Thr	Asp	Trp	Asp	Glu	Ser	Arg	Lys	Leu	Asn	Arg	Ile	Tyr	Lys
			165						170					175	
Phe	Gln	Gly	Lys	Ala	Trp	Asp	Trp	Glu	Val	Ser	Asn	Glu	Asn	Gly	Asn
		180					185						190		
Tyr	Asp	Tyr	Leu	Met	Tyr	Ala	Asp	Ile	Asp	Tyr	Asp	His	Pro	Asp	Val

-continued

195					200					205					
Ala	Ala	Glu	Ile	Lys	Arg	Trp	Gly	Thr	Trp	Tyr	Ala	Asn	Glu	Leu	Gln
210						215					220				
Leu	Asp	Gly	Phe	Arg	Leu	Asp	Ala	Val	Lys	His	Ile	Lys	Phe	Ser	Phe
225					230					235					240
Leu	Arg	Asp	Trp	Val	Asn	His	Val	Arg	Glu	Lys	Thr	Gly	Lys	Glu	Met
				245					250					255	
Phe	Thr	Val	Ala	Glu	Tyr	Trp	Gln	Asn	Asp	Leu	Gly	Ala	Leu	Glu	Asn
			260					265					270		
Tyr	Leu	Asn	Lys	Thr	Asn	Phe	Asn	His	Ser	Val	Phe	Asp	Val	Pro	Leu
	275					280					285				
His	Tyr	Gln	Phe	His	Ala	Ala	Ser	Thr	Gln	Gly	Gly	Gly	Tyr	Asp	Met
	290					295					300				
Arg	Lys	Leu	Leu	Asn	Gly	Thr	Val	Val	Ser	Lys	His	Pro	Leu	Lys	Ser
305					310					315					320
Val	Thr	Phe	Val	Asp	Asn	His	Asp	Thr	Gln	Pro	Gly	Gln	Ser	Leu	Glu
				325					330					335	
Ser	Thr	Val	Gln	Thr	Trp	Phe	Lys	Pro	Leu	Ala	Tyr	Ala	Phe	Ile	Leu
			340					345					350		
Thr	Arg	Glu	Ser	Gly	Tyr	Pro	Gln	Val	Phe	Tyr	Gly	Asp	Met	Tyr	Gly
	355					360					365				
Thr	Lys	Gly	Asp	Ser	Gln	Arg	Glu	Ile	Pro	Ala	Leu	Lys	His	Lys	Ile
	370					375					380				
Glu	Pro	Ile	Leu	Lys	Ala	Arg	Lys	Gln	Tyr	Ala	Tyr	Gly	Ala	Gln	His
385					390					395					400
Asp	Tyr	Phe	Asp	His	His	Asp	Ile	Val	Gly	Trp	Thr	Arg	Glu	Gly	Asp
				405					410					415	
Ser	Ser	Val	Ala	Asn	Ser	Gly	Leu	Ala	Ala	Leu	Ile	Thr	Asp	Gly	Pro
			420					425					430		
Gly	Gly	Ala	Lys	Arg	Met	Tyr	Val	Gly	Arg	Gln	Asn	Ala	Gly	Glu	Thr
			435					440					445		
Trp	His	Asp	Ile	Thr	Gly	Asn	Arg	Ser	Glu	Pro	Val	Val	Ile	Asn	Ser
	450					455					460				
Glu	Gly	Trp	Gly	Glu	Phe	His	Val	Asn	Gly	Gly	Ser	Val	Ser	Ile	Tyr
465					470					475					480
Val	Gln	Arg													

<210> SEQ ID NO 5

<211> LENGTH: 480

<212> TYPE: PRT

<213> ORGANISM: Bacillus amyloliquefaciens

<400> SEQUENCE: 5

Val	Asn	Gly	Thr	Leu	Met	Gln	Tyr	Phe	Glu	Trp	Tyr	Thr	Pro	Asn	Asp
1				5					10					15	
Gly	Gln	His	Trp	Lys	Arg	Leu	Gln	Asn	Asp	Ala	Glu	His	Leu	Ser	Asp
			20					25					30		
Ile	Gly	Ile	Thr	Ala	Val	Trp	Ile	Pro	Pro	Ala	Tyr	Lys	Gly	Leu	Ser
		35					40					45			
Gln	Ser	Asp	Asn	Gly	Tyr	Gly	Pro	Tyr	Asp	Leu	Tyr	Asp	Leu	Gly	Glu
	50					55				60					
Phe	Gln	Gln	Lys	Gly	Thr	Val	Arg	Thr	Lys	Tyr	Gly	Thr	Lys	Ser	Glu

-continued

65	70	75	80
Leu Gln Asp Ala Ile Gly Ser Leu His Ser Arg Asn Val Gln Val Tyr	85	90	95
Gly Asp Val Val Leu Asn His Lys Ala Gly Ala Asp Ala Thr Glu Asp	100	105	110
Val Thr Ala Val Glu Val Asn Pro Ala Asn Arg Asn Gln Glu Thr Ser	115	120	125
Glu Glu Tyr Gln Ile Lys Ala Trp Thr Asp Phe Arg Phe Pro Gly Arg	130	135	140
Gly Asn Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe Asp Gly	145	150	155
Ala Asp Trp Asp Glu Ser Arg Lys Ile Ser Arg Ile Phe Lys Phe Arg	165	170	175
Gly Glu Gly Lys Ala Trp Asp Trp Glu Val Ser Ser Glu Asn Gly Asn	180	185	190
Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Tyr Asp His Pro Asp Val	195	200	205
Val Ala Glu Thr Lys Lys Trp Gly Ile Trp Tyr Ala Asn Glu Leu Ser	210	215	220
Leu Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Lys Phe Ser Phe	225	230	235
Leu Arg Asp Trp Val Gln Ala Val Arg Gln Ala Thr Gly Lys Glu Met	245	250	255
Phe Thr Val Ala Glu Tyr Trp Gln Asn Asn Ala Gly Lys Leu Glu Asn	260	265	270
Tyr Leu Asn Lys Thr Ser Phe Asn Gln Ser Val Phe Asp Val Pro Leu	275	280	285
His Phe Asn Leu Gln Ala Ala Ser Ser Gln Gly Gly Gly Tyr Asp Met	290	295	300
Arg Arg Leu Leu Asp Gly Thr Val Val Ser Arg His Pro Glu Lys Ala	305	310	315
Val Thr Phe Val Glu Asn His Asp Thr Gln Pro Gly Gln Ser Leu Glu	325	330	335
Ser Thr Val Gln Thr Trp Phe Lys Pro Leu Ala Tyr Ala Phe Ile Leu	340	345	350
Thr Arg Glu Ser Gly Tyr Pro Gln Val Phe Tyr Gly Asp Met Tyr Gly	355	360	365
Thr Lys Gly Thr Ser Pro Lys Glu Ile Pro Ser Leu Lys Asp Asn Ile	370	375	380
Glu Pro Ile Leu Lys Ala Arg Lys Glu Tyr Ala Tyr Gly Pro Gln His	385	390	395
Asp Tyr Ile Asp His Pro Asp Val Ile Gly Trp Thr Arg Glu Gly Asp	405	410	415
Ser Ser Ala Ala Lys Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro	420	425	430
Gly Gly Ser Lys Arg Met Tyr Ala Gly Leu Lys Asn Ala Gly Glu Thr	435	440	445
Trp Tyr Asp Ile Thr Gly Asn Arg Ser Asp Thr Val Lys Ile Gly Ser	450	455	460
Asp Gly Trp Gly Glu Phe His Val Asn Asp Gly Ser Val Ser Ile Tyr	465	470	475
			480

-continued

```

<210> SEQ ID NO 6
<211> LENGTH: 485
<212> TYPE: PRT
<213> ORGANISM: Bacillus sp.

<400> SEQUENCE: 6
His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr
1      5      10
Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Asn Ser Asp Ala Ser
20     25     30
Asn Leu Lys Ser Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp
35     40     45
Lys Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr
50     55     60
Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly
65     70     75     80
Thr Arg Ser Gln Leu Gln Ala Ala Val Thr Ser Leu Lys Asn Asn Gly
85     90     95
Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp
100    105    110
Ala Thr Glu Met Val Arg Ala Val Glu Val Asn Pro Asn Asn Arg Asn
115    120    125
Gln Glu Val Thr Gly Glu Tyr Thr Ile Glu Ala Trp Thr Arg Phe Asp
130    135    140
Phe Pro Gly Arg Gly Asn Thr His Ser Ser Phe Lys Trp Arg Trp Tyr
145    150    155    160
His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Arg Leu Asn Asn Arg
165    170    175
Ile Tyr Lys Phe Arg Gly His Gly Lys Ala Trp Asp Trp Glu Val Asp
180    185    190
Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Met
195    200    205
Asp His Pro Glu Val Val Asn Glu Leu Arg Asn Trp Gly Val Trp Tyr
210    215    220
Thr Asn Thr Leu Gly Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His
225    230    235    240
Ile Lys Tyr Ser Phe Thr Arg Asp Trp Ile Asn His Val Arg Ser Ala
245    250    255
Thr Gly Lys Asn Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu
260    265    270
Gly Ala Ile Glu Asn Tyr Leu Gln Lys Thr Asn Trp Asn His Ser Val
275    280    285
Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Lys Ser Gly
290    295    300
Gly Asn Tyr Asp Met Arg Asn Ile Phe Asn Gly Thr Val Val Gln Arg
305    310    315    320
His Pro Ser His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro
325    330    335
Glu Glu Ala Leu Glu Ser Phe Val Glu Glu Trp Phe Lys Pro Leu Ala
340    345    350
Tyr Ala Leu Thr Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr

```

-continued

355					360					365					
Gly	Asp	Tyr	Tyr	Gly	Ile	Pro	Thr	His	Gly	Val	Pro	Ala	Met	Arg	Ser
370						375					380				
Lys	Ile	Asp	Pro	Ile	Leu	Glu	Ala	Arg	Gln	Lys	Tyr	Ala	Tyr	Gly	Lys
385						390					395				400
Gln	Asn	Asp	Tyr	Leu	Asp	His	His	Asn	Ile	Ile	Gly	Trp	Thr	Arg	Glu
				405					410					415	
Gly	Asn	Thr	Ala	His	Pro	Asn	Ser	Gly	Leu	Ala	Thr	Ile	Met	Ser	Asp
			420					425					430		
Gly	Ala	Gly	Gly	Ser	Lys	Trp	Met	Phe	Val	Gly	Arg	Asn	Lys	Ala	Gly
			435				440					445			
Gln	Val	Trp	Ser	Asp	Ile	Thr	Gly	Asn	Arg	Thr	Gly	Thr	Val	Thr	Ile
	450					455					460				
Asn	Ala	Asp	Gly	Trp	Gly	Asn	Phe	Ser	Val	Asn	Gly	Gly	Ser	Val	Ser
465						470					475				480
Ile	Trp	Val	Asn	Lys											
			485												

<210> SEQ ID NO 7

<211> LENGTH: 485

<212> TYPE: PRT

<213> ORGANISM: Bacillus sp.

<400> SEQUENCE: 7

His	His	Asn	Gly	Thr	Asn	Gly	Thr	Met	Met	Gln	Tyr	Phe	Glu	Trp	Tyr
1				5					10					15	
Leu	Pro	Asn	Asp	Gly	Asn	His	Trp	Asn	Arg	Leu	Arg	Asp	Asp	Ala	Ala
		20						25					30		
Asn	Leu	Lys	Ser	Lys	Gly	Ile	Thr	Ala	Val	Trp	Ile	Pro	Pro	Ala	Trp
		35					40					45			
Lys	Gly	Thr	Ser	Gln	Asn	Asp	Val	Gly	Tyr	Gly	Ala	Tyr	Asp	Leu	Tyr
	50					55					60				
Asp	Leu	Gly	Glu	Phe	Asn	Gln	Lys	Gly	Thr	Val	Arg	Thr	Lys	Tyr	Gly
65					70					75					80
Thr	Arg	Asn	Gln	Leu	Gln	Ala	Ala	Val	Thr	Ser	Leu	Lys	Asn	Asn	Gly
			85					90						95	
Ile	Gln	Val	Tyr	Gly	Asp	Val	Val	Met	Asn	His	Lys	Gly	Gly	Ala	Asp
		100						105					110		
Gly	Thr	Glu	Ile	Val	Asn	Ala	Val	Glu	Val	Asn	Arg	Ser	Asn	Arg	Asn
		115					120					125			
Gln	Glu	Thr	Ser	Gly	Glu	Tyr	Ala	Ile	Glu	Ala	Trp	Thr	Lys	Phe	Asp
	130					135					140				
Phe	Pro	Gly	Arg	Gly	Asn	Asn	His	Ser	Ser	Phe	Lys	Trp	Arg	Trp	Tyr
145					150					155					160
His	Phe	Asp	Gly	Thr	Asp	Trp	Asp	Gln	Ser	Arg	Gln	Leu	Gln	Asn	Lys
				165				170						175	
Ile	Tyr	Lys	Phe	Arg	Gly	Thr	Gly	Lys	Ala	Trp	Asp	Trp	Glu	Val	Asp
		180						185					190		
Thr	Glu	Asn	Gly	Asn	Tyr	Asp	Tyr	Leu	Met	Tyr	Ala	Asp	Val	Asp	Met
	195						200					205			
Asp	His	Pro	Glu	Val	Ile	His	Glu	Leu	Arg	Asn	Trp	Gly	Val	Trp	Tyr
	210					215					220				

-continued

Thr	Asn	Thr	Leu	Asn	Leu	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Val	Lys	His	225	230	235	240
Ile	Lys	Tyr	Ser	Phe	Thr	Arg	Asp	Trp	Leu	Thr	His	Val	Arg	Asn	Thr	245	250	255	
Thr	Gly	Lys	Pro	Met	Phe	Ala	Val	Ala	Glu	Phe	Trp	Lys	Asn	Asp	Leu	260	265	270	
Gly	Ala	Ile	Glu	Asn	Tyr	Leu	Asn	Lys	Thr	Ser	Trp	Asn	His	Ser	Val	275	280	285	
Phe	Asp	Val	Pro	Leu	His	Tyr	Asn	Leu	Tyr	Asn	Ala	Ser	Asn	Ser	Gly	290	295	300	
Gly	Tyr	Tyr	Asp	Met	Arg	Asn	Ile	Leu	Asn	Gly	Ser	Val	Val	Gln	Lys	305	310	315	320
His	Pro	Thr	His	Ala	Val	Thr	Phe	Val	Asp	Asn	His	Asp	Ser	Gln	Pro	325	330	335	
Gly	Glu	Ala	Leu	Glu	Ser	Phe	Val	Gln	Gln	Trp	Phe	Lys	Pro	Leu	Ala	340	345	350	
Tyr	Ala	Leu	Val	Leu	Thr	Arg	Glu	Gln	Gly	Tyr	Pro	Ser	Val	Phe	Tyr	355	360	365	
Gly	Asp	Tyr	Tyr	Gly	Ile	Pro	Thr	His	Gly	Val	Pro	Ala	Met	Lys	Ser	370	375	380	
Lys	Ile	Asp	Pro	Leu	Leu	Gln	Ala	Arg	Gln	Thr	Phe	Ala	Tyr	Gly	Thr	385	390	395	400
Gln	His	Asp	Tyr	Phe	Asp	His	His	Asp	Ile	Ile	Gly	Trp	Thr	Arg	Glu	405	410	415	
Gly	Asn	Ser	Ser	His	Pro	Asn	Ser	Gly	Leu	Ala	Thr	Ile	Met	Ser	Asp	420	425	430	
Gly	Pro	Gly	Gly	Asn	Lys	Trp	Met	Tyr	Val	Gly	Lys	Asn	Lys	Ala	Gly	435	440	445	
Gln	Val	Trp	Arg	Asp	Ile	Thr	Gly	Asn	Arg	Thr	Gly	Thr	Val	Thr	Ile	450	455	460	
Asn	Ala	Asp	Gly	Trp	Gly	Asn	Phe	Ser	Val	Asn	Gly	Gly	Ser	Val	Ser	465	470	475	480
Val	Trp	Val	Lys	Gln												485			

<210> SEQ ID NO 8

<211> LENGTH: 485

<212> TYPE: PRT

<213> ORGANISM: Bacillus sp.

<400> SEQUENCE: 8

His	His	Asn	Gly	Thr	Asn	Gly	Thr	Met	Met	Gln	Tyr	Phe	Glu	Trp	His	1	5	10	15
Leu	Pro	Asn	Asp	Gly	Asn	His	Trp	Asn	Arg	Leu	Arg	Asp	Asp	Ala	Ser	20	25	30	
Asn	Leu	Arg	Asn	Arg	Gly	Ile	Thr	Ala	Ile	Trp	Ile	Pro	Pro	Ala	Trp	35	40	45	
Lys	Gly	Thr	Ser	Gln	Asn	Asp	Val	Gly	Tyr	Gly	Ala	Tyr	Asp	Leu	Tyr	50	55	60	
Asp	Leu	Gly	Glu	Phe	Asn	Gln	Lys	Gly	Thr	Val	Arg	Thr	Lys	Tyr	Gly	65	70	75	80
Thr	Arg	Ser	Gln	Leu	Glu	Ser	Ala	Ile	His	Ala	Leu	Lys	Asn	Asn	Gly	85	90	95	

[illegible]

-continued

<210> SEQ ID NO 9
 <211> LENGTH: 1455
 <212> TYPE: DNA
 <213> ORGANISM: *Bacillus* sp.

<400> SEQUENCE: 9

```

catcataatg gaacaaatgg tactatgatg caatatttcg aatgggtattt gccaaatgac      60
gggaatcatt ggaacagggt gagggatgac gcagctaact taaagagtaa agggataaca      120
gctgtatgga tcccacctgc atggaagggg acttcccaga atgatgtagg ttatggagcc      180
tatgatattat atgatcttgg agagttaaac cagaagggga cggttcgtac aaaatatgga      240
acacgcaacc agctacagcg tgcggtgacc tctttaaaaa ataacggcat tcaggatatat      300
ggtgatgtcg tcatgaatca taaagggtgga gcagatggta cggaaattgt aaatgcggta      360
gaagtgaatc ggagcaaccg aaaccaggaa acctcaggag agtatgcaat agaagcgtgg      420
acaaagtttg attttcctgg aagaggaaat aaccattcca gctttaagtg gcgctgggat      480
cattttgatg ggacagattg ggatcagtcg cgccagcttc aaaacaaaat atataaattc      540
aggggaacag gcaagccctg ggactgggaa gtcgatacag agaatggcaa ctatgactat      600
cttatgtatg cagacgtgga tatggatcac ccagaagtaa tacatgaact tagaaaactgg      660
ggagtgtggt atacgaatac actgaacctt gatggattta gaatagatgc agtgaaacat      720
ataaaatata gctttacgag agattggcct acacatgtgc gtaacaccac aggtaaacca      780
atgtttgcag tggctgagtt ttggaaaaat gaccttgggt caattgaaaa ctatttgaat      840
aaaacaagtt ggaatcactc ggtgtttgat gttcctctcc actataattt gtacaatgca      900
tctaatagcg gtgggtatta tgatatgaga aatattttta atggttctgt ggtgcaaaaa      960
catccaacac atgccgttac ttttgttgat aaccatgatt ctacagcccg ggaagcattg     1020
gaatcctttg ttcaacaatg gtttaaacca cttgcatatg cattggttct gacaagggaa     1080
caaggttatc ctccgttatt ttatggggat tactacggta tccaaccca tgggtgttcg     1140
gctatgaaat ctaaaataga cctcttctcg caggcacgtc aaacttttgc ctatggtagc     1200
cagcatgatt actttgatca tcatgatatt atcggttgga caagagaggg aaatagctcc     1260
catocaaatt caggccttgc caccattatg tcagatggtc caggtggtaa caaatggatg     1320
tatgtgggga aaaataaagc gggacaagtt tggagagata ttaccggaaa taggacaggc     1380
accgtcacia ttaatgcaga cggatggggg aatttctctg ttaatggagg gtcggtttcg     1440
gtttgggtga agcaa                                           1455

```

<210> SEQ ID NO 10
 <211> LENGTH: 1455
 <212> TYPE: DNA
 <213> ORGANISM: *Bacillus* sp.

<400> SEQUENCE: 10

```

catcataatg ggacaaatgg gacgatgatg caatactttg aatggcactt gcctaattgat      60
gggaatcact ggaatagatt aagagatgat gctagtaatc taagaaatag aggtataacc     120
gctatttggg ttccgcctgc ctggaaaggg acttcgcaa atgatgtggg gtatggagcc     180
tatgatcttt atgatttagg ggaatttaac caaaagggga cggttcgtac taagtatggg     240
acacgtagtc aattggagtc tgccatccat gctttaaaga ataatggcgt tcaagtttat     300

```

-continued

```

ggggatgtag tgatgaacca taaaggagga gctgatgcta cagaaaacgt tcttgcgtgc 360
gaggtgaatc caaataaccg gaatcaagaa atatctgggg actacacaat tgaggcttgg 420
actaagtttg attttccagg gaggggtaat acatactcag actttaaatg gcgttggtat 480
catttcgatg gtgtagattg ggatcaatca cgacaattcc aaaatcgtat ctacaaattc 540
cgaggatgat gtaaggcatg ggattgggaa gtagattcgg aaaatggaaa ttatgattat 600
ttaatgtatg cagatgtaga tatggatcat cggaggttag taaatgagct tagaagatgg 660
ggagaatggt atacaaatac attaaatctt gatggattta ggatcgatgc ggtgaagcat 720
attaaatata gctttacacg tgattggttg acccatgtaa gaaacgcaac gggaaaagaa 780
atgtttgctg ttgctgaatt ttggaaaaat gatttaggtg ccttgagaaa ctatttaaat 840
aaaacaaact ggaatcattc tgtctttgat gtcccccttc attataatct ttataacgcg 900
tcaaatagtg gaggcaacta tgacatggca aaacttctta atggaacggg tgttcaaaag 960
catccaatgc atgccgaac ttttgtggat aatcacgatt ctcaacctgg ggaatcatta 1020
gaatcatttg tacaagaatg gtttaagcca cttgcttatg cgcttatttt aacaagagaa 1080
caaggctatc cctctgtctt ctatggtgac tactatggaa ttccaacaca tagtgtccca 1140
gcaatgaaag ccaagattga tccaatctta gaggcgcgtc aaaattttgc atatggaaca 1200
caacatgatt attttgacca tcataatata atcggatgga cacgtgaagg aaataccacg 1260
catcccaatt caggacttgc gactatcatg tcggatgggc cagggggaga gaaatggatg 1320
tacgtagggc aaaataaagc aggtcaagtt tggcatgaca taactggaaa taaaccagga 1380
acagttacga tcaatgcaga tggatgggct aatttttcag taaatggagg atctgtttcc 1440
atttgggtga aacga 1455

```

<210> SEQ ID NO 11

<211> LENGTH: 1548

<212> TYPE: DNA

<213> ORGANISM: *Bacillus stearothermophilus*

<400> SEQUENCE: 11

```

gccgcaccgt ttaacggcac catgatgcag tattttgaat ggtacttgcc ggatgatggc 60
acgttatgga ccaaagtggc caatgaagcc aacaacttat ccagccttgg catcaccgct 120
ctttggctgc cgcccgtta caaaggaaca agccgcagcg acgtagggtg cggagtatac 180
gacttgtagt acctcggcga attcaatcaa aaagggaccg tccgcacaaa atacggaaca 240
aaagctcaat atcttcaagc cattcaagcc gcccacgccc ctggaatgca agtgtacgcc 300
gatgtcgtgt tcgaccataa aggcggcgct gacggcacgg aatgggtgga cgcgctcgaa 360
gtcaatccgt ccgaccgcaa ccaagaaatc tcgggcacct atcaaatcca agcatggacg 420
aaatttgatt ttcccgggcg gggcaacacc tactccagct ttaagtggcg ctggtaccat 480
tttgacggcg ttgattggga cgaaagccga aaattgagcc gcatttaca attccgggc 540
atcggcaaag cgtgggattg ggaagtagac acggaaaacg gaaactatga ctacttaatg 600
tatgccgacc ttgatatgga tcatcccgaa gtcgtgaccg agctgaaaaa ctgggggaaa 660
tggtatgtca acacaacgaa cattgatggg ttccggcttg atgccgtcaa gcatattaag 720
ttcagttttt ttctgattg gttgtcgtat gtgcgttctc agactggcaa gccgctat 780
accgtcgggg aatattggag ctatgacatc aacaagttgc acaattacat tacgaaaaca 840

```

-continued

gacggaacga tgtctttgtt tgatgccccg ttacacaaca aattttatac cgcttcacaa	900
tcagggggcg catttgatat gcgcacgtta atgaccaata ctctcatgaa agatcaaccg	960
acattggccg tcaccttcgt tgataatcat gacaccgaac ccggccaagc gctgcagtca	1020
tgggtcgacc catggttcaa accgttggct tacgccttta ttctaactcg gcaggaagga	1080
taccctgctg tcttttatgg tgactattat ggcattccac aatataacat tccttcgctg	1140
aaaagcaaaa tcgatccgct cctcatcgcg cgcagggtt atgcttacgg aacgcaacat	1200
gattatcttg atcactccga catcatcggg tggacaaggg aagggggcac tgaanaacca	1260
ggatccggac tggccgcact gatcaccgat gggccgggag gaagcaaatg gatgtacgtt	1320
ggcaacaac acgctggaaa agtgttctat gaccttacgg gcaaccggag tgacaccgtc	1380
accatcaaca gtgatggatg ggggaattc aaagtcaatg gcggttcggt ttcggtttgg	1440
gttcctagaa aaacgaccgt ttctaccatc gctcgccga tcacaaccg accgtggact	1500
ggtgaattcg tccgttggac cgaaccacgg ttggtggcat ggcttga	1548

<210> SEQ ID NO 12

<211> LENGTH: 1920

<212> TYPE: DNA

<213> ORGANISM: Bacillus licheniformis

<400> SEQUENCE: 12

cggaagattg gaagtacaaa aataagcaaa agattgtcaa tcatgtcatg agccatgcgg	60
gagacggaaa aatcgtctta atgcacgata tttatgcaac gttcgcagat gctgctgaag	120
agattattaa aaagctgaaa gcaaaaggct atcaattggg aactgtatct cagcttgaag	180
aagtgaagaa gcagagaggc tattgaataa atgagtagaa gcgccatctc ggcgcttttc	240
ttttggaaga aaatataggg aaaatggtag ttgttaaaaa ttcggaatat ttatacaaca	300
tcatatgttt cacattgaaa ggggaggaga atcatgaaac aacaaaaacg gctttacgcc	360
cgattgctga cgctgttatt tgcgctcctc ttcttgctgc ctcatctctc agcagcgccg	420
gcaaattctta atgggacgct gatgcagtat tttgaatggg acatgcccaa tgacggccaa	480
cattggaggc gtttgcaaaa cgactcggca tatttggtcg aacacggtat tactgccgtc	540
tggattcccc cggcatataa gggaacgagc caagcggatg tgggtacagg tgcttacgac	600
ctttatgatt taggggagtt tcatcaaaaa gggacgggtc ggacaaaagta cggcacaaaa	660
ggagagctgc aatctgcgat caaaagtctt cattcccgcg acattaacgt ttacggggat	720
gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc	780
gatcccgcgt accgcaaccg cgtaatttca ggagaacacc taattaaagc ctggacacat	840
tttcattttc cggggcgccg cagcacatcc agcgatttta aatggcattg gtaccatttt	900
gacggaaccg attgggacga gtcccgaag ctgaaccgca tctataagtt tcaaggaaag	960
gcttgggatt gggaagtctc caatgaaaac ggcaactatg attatttgat gtatgccgac	1020
atcgattatg accatcctga tgtcgcagca gaaattaaga gatggggcac ttggtatgcc	1080
aatgaactgc aattggacgg tttccgtctt gatgctgtca aacacattaa attttctttt	1140
ttgctgggatt ggggttaatca tgtcagggaa aaaacgggga aggaaatgtt tacggtagct	1200
gaatattggc agaattgactt gggcgcgctg gaaaactatt tgaacaaaac aaattttaat	1260
cattcagtggt ttgacgtgcc gcttcattat cagttccatg ctgcatcgac acagggaggc	1320

-continued

ggctatgata tgaggaaatt gctgaacggt acggtcgttt ccaagcatcc gttgaaatcg	1380
gttacatttg tcgataacca tgatacacag ccggggcaat cgcttgagtc gactgtccaa	1440
acatggttta agccgcttgc ttacgctttt attctcacia gggaatctgg ataccctcag	1500
gttttctacg gggatatgta cgggacgaaa ggagactccc agcgcgaaat tctgccttg	1560
aaacacaaaa ttgaaccgat cttaaaagcg agaaaacagt atgcgtacgg agcacagcat	1620
gattatttcg accaccatga cattgtcggc tggacaaggg aagcgacag ctcggttgca	1680
aattcagggt tggcggcatt aataacagac ggacccggtg gggcaaagcg aatgtatgtc	1740
ggccggcaaa acgcccgtga gacatggcat gacattaccg gaaaccgttc ggagccggtt	1800
gtcatcaatt cggaaggctg gggagagttt cacgtaaacg gcgggtcggt tccaatttat	1860
gttcaaagat agaagagcag agaggacgga tttcctgaag gaaatccgtt tttttat	1920

<210> SEQ ID NO 13

<400> SEQUENCE: 13

000

<210> SEQ ID NO 14

<211> LENGTH: 1455

<212> TYPE: DNA

<213> ORGANISM: *Bacillus* sp.

<400> SEQUENCE: 14

catcataatg ggacaaatgg gacgatgatg caatactttg aatggcactt gcctaattgat	60
gggaatcact ggaatagatt aagagatgat gctagtaatc taagaaatag aggtataacc	120
gctatttgga ttccgcctgc ctggaaaggg acttcgcaaa atgatgtggg gtatggagcc	180
tatgatcttt atgatttagg ggaattttaat caaaagggga cggttcgtag taagtatggg	240
acacgtagtc aattggagtc tgccatccat gctttaaaga ataatggcgt tcaagtttat	300
ggggatgtag tgatgaacca taaaggagga gctgatgcta cagaaaacgt tcttgcgtgc	360
gagggtgaatc caaataaccg gaatcaagaa atatctgggg actacacaat tgaggcttgg	420
actaagtttg attttccagg gaggggtaat acatactcag actttaaatg gcgttggtat	480
catttcgatg gtgtagattg ggatcaatca cgacaattcc aaaatcgtag ctacaaattc	540
cgaggatgat gtaaggcatg ggattgggaa gtagattcgg aaaatggaaa ttatgattat	600
ttaatgtatg cagatgtaga tatggatcat ccggaggtag taaatgagct tagaagatgg	660
ggagaatggt atacaaatac attaaatctt gatggattta ggatcgatgc ggtgaagcat	720
attaaatata gctttacacg tgattgggtg acccatgtaa gaaacgcaac gggaaaagaa	780
atgtttgctg ttgctgaatt ttggaaaaat gatttaggtg ccttgagaaa ctatttaaat	840
aaaacaaact ggaatcattc tgtctttgat gtcccccctc attataatct ttataacgcg	900
tcaaatagtg gaggcaacta tgacatggca aaacttctta atggaacggt tgttcaaaag	960
catccaatgc atgccgtaac ttttgtggat aatcacgatt ctcaacctgg ggaatcatta	1020
gaatcatttg tacaagaatg gtttaagcca cttgcttatg cgcttat	1080
caaggctatc cctctgtctt ctatgggtgac tactatggaa ttccaacaca tagtgtccca	1140
gcaatgaaag ccaagattga tccaatctta gaggcgcgtc aaaat	1200
caacatgatt attttgacca tcataatata atcggtgga cacgtgaagg aaataccacg	1260

-continued

catcccaatt caggacttgc gactatcatg tcggatgggc cagggggaga gaaatggatg 1320
tacgtagggc aaaataaagc aggtcaagtt tggcatgaca taactggaaa taaaccagga 1380
acagttacga tcaatgcaga tggatgggct aatttttcag taaatggagg atctgtttcc 1440
atttgggtga aacga 1455

<210> SEQ ID NO 15
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Forward Primer FSA

<400> SEQUENCE: 15

caaaatcgta tctacaaatt cmrkrsyarg dvktgggatt sggaagtaga ttcggaaaat 60

<210> SEQ ID NO 16
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Reverse Primer RSA

<400> SEQUENCE: 16

gaattttag atacgatttt g 21

<210> SEQ ID NO 17
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer sequence

<400> SEQUENCE: 17

cgattgctga cgctgttatt tgcg 24

<210> SEQ ID NO 18
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer sequence

<400> SEQUENCE: 18

cttgttcct tgtcagaacc aatg 24

<210> SEQ ID NO 19
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer 101458

<400> SEQUENCE: 19

gtcatagttg ccgaaatctg tatcgacttc 30

<210> SEQ ID NO 20
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer 101638

-continued

<400> SEQUENCE: 20

cccagtccca cgtacgtccc ctgaatttat atattttg

38

<210> SEQ ID NO 21

<211> LENGTH: 38

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Oligo 1

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (12)..(12)

<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 21

cccagtccca gntctttccc ctgaatttat atattttg

38

<210> SEQ ID NO 22

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer X2

<400> SEQUENCE: 22

gcgtggacaa agtttgattt tcttg

25

<210> SEQ ID NO 23

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer DA01

<400> SEQUENCE: 23

cctaattgatg ggaatcactg g

21

<210> SEQ ID NO 24

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer DA03

<400> SEQUENCE: 24

gcattggatg cttttgaaca accg

24

<210> SEQ ID NO 25

<211> LENGTH: 26

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer DA07

<400> SEQUENCE: 25

cgcaaaatga tatcgggtat ggagcc

26

<210> SEQ ID NO 26

<211> LENGTH: 29

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer DA20

-continued

<400> SEQUENCE: 26

gtgatgaacc acswaggtgg agctgatgc

29

<210> SEQ ID NO 27

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer DA14

<400> SEQUENCE: 27

gatggtgtat ggrycaatca cgacaattcc

30

<210> SEQ ID NO 28

<211> LENGTH: 28

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer DA15

<400> SEQUENCE: 28

ggtgtatggg ataactcacg acaattcc

28

<210> SEQ ID NO 29

<211> LENGTH: 28

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer DA16

<400> SEQUENCE: 29

ggtgtatggg atctctcacg acaattcc

28

<210> SEQ ID NO 30

<211> LENGTH: 32

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer DA17

<400> SEQUENCE: 30

gggatcaatc acgaaatttc caaaatcgta tc

32

<210> SEQ ID NO 31

<211> LENGTH: 32

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer DA18

<400> SEQUENCE: 31

gggatcaatc acgactcttc caaaatcgta tc

32

<210> SEQ ID NO 32

<211> LENGTH: 34

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer DA06

<400> SEQUENCE: 32

ggaaattatg attatatcat gtatgcagat gtag

34

-continued

<210> SEQ ID NO 33
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer DA09

<400> SEQUENCE: 33

gctgaatttt ggtcgaatga tttaggtgcc

30

<210> SEQ ID NO 34
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer DA11

<400> SEQUENCE: 34

gctgaatttt ggtcgaatga tttaggtgcc

30

<210> SEQ ID NO 35
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer DA21

<400> SEQUENCE: 35

gaattttgga agtacgattt aggtcgg

27

<210> SEQ ID NO 36
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer DA12

<400> SEQUENCE: 36

ggaaaaacga trycgtgcc ttggagaac

29

<210> SEQ ID NO 37
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer DA13

<400> SEQUENCE: 37

gatttaggtg cctrycagaa ctattta

27

<210> SEQ ID NO 38
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer DA08

<400> SEQUENCE: 38

cccccttcat gagaatcttt ataacg

26

<210> SEQ ID NO 39
<211> LENGTH: 25

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer DA04

<400> SEQUENCE: 39

gaatccgaac ctcattacac attcg

25

<210> SEQ ID NO 40
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer DA05

<400> SEQUENCE: 40

cggatggact cgagaaggaa ataccacg

28

<210> SEQ ID NO 41
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer DA10

<400> SEQUENCE: 41

cgtagggcaa aatcaggccg gtcaagtttg g

31

<210> SEQ ID NO 42
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer DA22

<400> SEQUENCE: 42

cataactgga aatcgcccg gaacagttac g

31

<210> SEQ ID NO 43
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer DA19

<400> SEQUENCE: 43

ctggaaataa awccggaaca gttacg

26

<210> SEQ ID NO 44
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer DA23

<400> SEQUENCE: 44

ggaaataaac caggaccctg tacgatcaat gc

32

<210> SEQ ID NO 45
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer DA32

-continued

<400> SEQUENCE: 45

gaggcttgga ctaggtttga ttttcag

28

<210> SEQ ID NO 46

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer DA31

<400> SEQUENCE: 46

gctgaatttt ggcgcaatga tttaggtgcc

30

<210> SEQ ID NO 47

<211> LENGTH: 34

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer bm4

<400> SEQUENCE: 47

gtgtttgacg tcccgtttca tgagaattta cagg

34

<210> SEQ ID NO 48

<211> LENGTH: 34

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer bm5

<400> SEQUENCE: 48

gtgtttgacg tcccgtttca taagaattta cagg

34

<210> SEQ ID NO 49

<211> LENGTH: 34

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer bm6

<400> SEQUENCE: 49

gtgtttgacg tcccgtttca tgccaattta cagg

34

<210> SEQ ID NO 50

<211> LENGTH: 32

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer bm8

<400> SEQUENCE: 50

agggaatccg gataccctga ggttttctac gg

32

<210> SEQ ID NO 51

<211> LENGTH: 34

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer bm11

<400> SEQUENCE: 51

gatgtggttt tggatcataa ggccggcgct gatg

34

-continued

<210> SEQ ID NO 52
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer p1

<400> SEQUENCE: 52

ctgttattaa tgccgcaaaa cc 22

<210> SEQ ID NO 53
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer p2

<400> SEQUENCE: 53

ggaaaagaaa tgtttacggt tgcg 24

<210> SEQ ID NO 54
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer p3

<400> SEQUENCE: 54

gaaatgaagc ggaacatcaa acacg 25

<210> SEQ ID NO 55
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer p4

<400> SEQUENCE: 55

gtatgattta ggagaattcc 20

<210> SEQ ID NO 56
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer b11

<400> SEQUENCE: 56

ccagcgcgcc taggtcacgc tgccaatatt cag 33

<210> SEQ ID NO 57
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer b12

<400> SEQUENCE: 57

ccagcgcgcc taggtcatcc tgccaatatt cag 33

<210> SEQ ID NO 58
<211> LENGTH: 2084

-continued

<212> TYPE: DNA

<213> ORGANISM: *Bacillus amyloliquefaciens*

<400> SEQUENCE: 58

```

gccccgcaca tacgaaaaga ctggctgaaa acattgagcc tttgatgact gatgatttgg      60
ctgaagaagt ggatcgattg tttgagaaaa gaagaagacc ataaaaatac cttgtctgtc      120
atcagacagg gtatttttta tgctgtccag actgtccgct gtgtaaaaat aaggaataaa      180
ggggggttgt tattatttta ctgatatgta aaatataatt tgtataagaa aatgagaggg      240
agaggaaaca tgattcaaaa acgaaagcgg acagtttcgt tcagacttgt gcttatgtgc      300
acgctgttat ttgtcagttt gccgattaca aaaacatcag ccgtaaatgg cacgctgatg      360
cagtattttg aatgggtata gccgaacgac ggccagcatt ggaaacgatt gcagaatgat      420
gcggaacatt tatcggatat cggaatcact gccgtctgga ttctctccgc atacaaagga      480
ttgagccaat ccgataacgg atacggacct tatgatttgt atgatttagg agaattccag      540
caaaaaggga cggtcagaac gaaatacggc acaaaatcag agcttcaaga tgcgatcggc      600
tctactgcatt ccggaacgt ccaagtatac ggagatgtgg ttttgaatca taaggctggt      660
gctgatgcaa cagaagatgt aactgccgtc gaagtcaatc cggccaatag aaatcaggaa      720
acttcggagg aatatcaaat caaagcgtgg acggattttc gttttccggg ccgtggaaac      780
acgtacagtg attttaaatg gcattggtat catttcgacg gageggactg ggatgaatcc      840
cggaagatca gccgcattct taagtttcgt ggggaaggaa aagcgtggga ttgggaagta      900
tcaagtgaac acggcaacta tgactattta atgtatgctg atgttgacta cgaccaccct      960
gatgtcgtgg cagagacaaa aaaatggggg atctggtatg cgaatgaact gtcattagac     1020
ggcttccgta ttgatgccgc caaacatatt aaattttcat ttctgcgtga ttgggttcag     1080
gcggtcagac aggcgacggg aaaagaaatg tttacggttg cggagtattg gcagaataat     1140
gccgggaaac tcgaaaaacta cttgaataaa acaagcttta atcaatccgt gtttgatgtt     1200
ccgcttcatt tcaatttaca ggcggtctcc tcacaaggag gcggatatga tatgaggcgt     1260
ttgctggacg gtaccgttgt gtccaggcat ccgaaaaagg cggttacatt tgttgaaaat     1320
catgacacac agccgggaca gtcattggaa tcgacagtcc aaacttggtt taaaccgctt     1380
gcatacgcct ttattttgac aagagaatcc ggttatcctc aggtgttcta tggggatatg     1440
tacgggacaa aagggaacac gccaaaggaa attccctcac tgaagataa tatagagccg     1500
attttaaaag cgcgtaaggga gtacgcatac gggccccagc acgattatat tgaccaccg     1560
gatgtgatcg gatggacgag ggaagggtgac agctccgccc ccaaatcagg tttggccgct     1620
ttaatcacgg acggacccgg cggatcaaag cggatgtatg ccggcctgaa aaatgccggc     1680
gagacatggt atgacataac gggcaaccgt tcagatactg taaaaatcgg atctgacggc     1740
tggggagagt ttcattgtaa cgatgggtcc gtctccattt atgttcagaa ataaggtaat     1800
aaaaaaacac ctccaagctg agtgcgggta tcagcttgga ggtgcgttta ttttttcagc     1860
cgtatgacaa ggtcggcatc aggtgtgaca aatacggtat gctggctgtc ataggtgaca     1920
aatccggggt ttgcgcgctt tggctttttc acatgtctga tttttgtata atcaacaggc     1980
acggagccgg aatcttttcg cttggaaaaa taagcggcga tcgtagctgc ttccaatatg     2040
gattgttcat cgggatcgct gcttttaato acaacgtggg atcc                                2084

```

1. A variant alpha-amylase of a parent alpha-amylase, wherein the variant has alpha-amylase activity, and at least 95% homology with the amino acid sequence shown in SEQ ID. NO. 3 comprising one or more of the following substitutions (using SEQ ID NO: 3 for numbering):

I181A,R,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y, or V, wherein the variant has increased specific activity relative to the parent alpha-amylase, wherein specific activity is determined at a temperature of 10° C. to 60° C.

2. A variant alpha-amylase of a parent alpha-amylase, wherein the variant has alpha-amylase activity, and wherein the variant has at least 97% homology with SEQ ID. NO. 3 comprising one or more of the following substitutions (using SEQ ID NO: 3 for numbering):

I181A,R,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y, or V, wherein the variant has increased specific activity relative to the parent alpha-amylase when determined at a temperature of 10° C. to 60° C.

3. The variant of claim 2, wherein the variant comprises a substitution of I181A.

4. The variant of claim 2, wherein the variant comprises a substitution of I181R.

5. The variant of claim 2, wherein the variant comprises a substitution of I181N.

6. The variant of claim 2, wherein the variant comprises a substitution of I181C.

7. The variant of claim 2, wherein the variant comprises a substitution of I181E.

8. The variant of claim 2, wherein the variant comprises a substitution of I181Q.

9. The variant of claim 2, wherein the variant comprises a substitution of I181G.

10. The variant of claim 2, wherein the variant comprises a substitution of I181H.

11. The variant of claim 2, wherein the variant comprises a substitution of I181L.

12. The variant of claim 2, wherein the variant comprises a substitution of I181K.

13. The variant of claim 2, wherein the variant comprises a substitution of I181M.

14. The variant of claim 2, wherein the variant comprises a substitution of I181F.

15. The variant of claim 2, wherein the variant comprises a substitution of I181P.

16. The variant of claim 2, wherein the variant comprises a substitution of I181S.

17. The variant of claim 2, wherein the variant comprises a substitution of I181T.

18. The variant of claim 2, wherein the variant comprises a substitution of I181W.

19. The variant of claim 2, wherein the variant comprises a substitution of I181Y.

20. The variant of claim 2, wherein the variant comprises a substitution of I181V.

21. A variant alpha-amylase of a parent alpha-amylase, which variant has alpha-amylase activity and at least 95% homology with the amino acid sequence shown in SEQ ID. NO. 3, comprising a substitution (using SEQ ID NO: 3 for numbering):

at position 181, wherein the variant has increased specific activity relative to the parent alpha-amylase, wherein the specific activity is determined at a temperature of 20° C. to 50° C.

22. A variant of a parent alpha-amylase, which variant has alpha-amylase activity, has at least 95% homology with the amino acid sequence shown in SEQ ID. NO. 3, comprising a substitution (using SEQ ID NO: 3 for numbering):

at position 181, wherein the variant has increased specific activity relative to the parent alpha-amylase, wherein the specific activity is determined at a temperature of 30° C. to 40° C.

23. The variant of claim 2, wherein the variant has at least 99% homology with SEQ ID. NO. 3.

* * * * *